UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June~~September 30, 2021

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-33678

NOVABAY PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	68-0454536
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

2000 Powell Street, Suite 1150, Emeryville, CA 94608

(Address of principal executive offices) (Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 899-8800

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange On Which Registered
Common Stock, par value $0.01 per share	NBY	NYSE American

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☐	Accelerated filer	☐	Emerging growth company	☐
Non-accelerated filer	☒	Smaller reporting company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~August~~November 10, 2021, there were 44,943,364 shares of the registrant’s common stock outstanding.

Table of Contents

NOVABAY PHARMACEUTICALS, INC.

TABLE OF CONTENTS

PART I	PART I			PART I
FINANCIAL INFORMATION	FINANCIAL INFORMATION			FINANCIAL INFORMATION

Item 1.		Financial Statements	3		Financial Statements	3

	1.	Condensed Consolidated Balance Sheets: June 30, 2021 (unaudited) and December 31, 2020	3	1.	Condensed Consolidated Balance Sheets: September 30, 2021 (unaudited) and December 31, 2020	3

	2.	Condensed Consolidated Statements of Operations and Comprehensive Loss: Three and six months ended June 30, 2021 and 2020 (unaudited)	4	2.	Condensed Consolidated Statements of Operations and Comprehensive Loss: Three and nine months ended September 30, 2021 and 2020 (unaudited)	4

	3.	Condensed Consolidated Statements of Stockholders’ Equity (Deficit): Three and six months ended June 30, 2021 and 2020 (unaudited)	5	3.	Condensed Consolidated Statements of Stockholders’ Equity (Deficit): Three and nine months ended September 30, 2021 and 2020 (unaudited)	5

	4.	Condensed Consolidated Statements of Cash Flows: Six months ended June 30, 2021 and 2020 (unaudited)	6	4.	Condensed Consolidated Statements of Cash Flows: Nine months ended September 30, 2021 and 2020 (unaudited)	6

	5.	Notes to Condensed Consolidated Financial Statements (unaudited)	8	5.	Notes to Condensed Consolidated Financial Statements (unaudited)	8

Item 2.		Management’s Discussion and Analysis of Financial Condition and Results of Operations	30		Management’s Discussion and Analysis of Financial Condition and Results of Operations	31

Item 3.		Quantitative and Qualitative Disclosures About Market Risk	41		Quantitative and Qualitative Disclosures About Market Risk	42

Item 4.		Controls and Procedures	41		Controls and Procedures	42

PART II	PART II			PART II
OTHER INFORMATION	OTHER INFORMATION			OTHER INFORMATION

Item 1.		Legal Proceedings	41		Legal Proceedings	42

Item 1A.		Risk Factors	41		Risk Factors	42

Item 2.		Unregistered Sales of Equity Securities and Use of Proceeds	42		Unregistered Sales of Equity Securities and Use of Proceeds	43

Item 3.		Defaults Upon Senior Securities	42		Defaults Upon Senior Securities	43

Item 4.		Mine Safety Disclosure	42		Mine Safety Disclosure	43

Item 5.		Other Information	42		Other Information	43

Item 6.		Exhibits	43		Exhibits	44

SIGNATURES	SIGNATURES		44	SIGNATURES		45

EXHIBIT INDEX	EXHIBIT INDEX		43	EXHIBIT INDEX		44

Unless the context requires otherwise, all references in this report to “we,” “our,” “us,” the “Company” and “NovaBay” refer to NovaBay Pharmaceuticals, Inc.

NovaBay®, NovaBay Pharma®, Avenova®, NeutroPhase®, CelleRx®, Aganocide®, AgaDerm®, Neutrox® and Going Beyond Antibiotics® are trademarks of NovaBay Pharmaceuticals, Inc. All other trademarks and trade names are the property of their respective owners.

Table of Contents

	June 30,			December 31,			September 30,			December 31,
	2021			2020			2021			2020
	(Unaudited)						(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	10,294		$	11,952		$	9,028		$	11,952
Accounts receivable, net of allowance for doubtful accounts ($0 at June 30, 2021 and December 31, 2020)		1,232			1,106
Inventory, net of allowance for excess and obsolete inventory ($185 and $236 at June 30, 2021 and December 31, 2020, respectively)		682			608
Accounts receivable, net of allowance for doubtful accounts ($0 at September 30, 2021 and December 31, 2020)								843			1,106
Inventory, net of allowance for excess and obsolete inventory ($149 and $236 at September 30, 2021 and December 31, 2020, respectively)								969			608
Prepaid expenses and other current assets		564			576			657			576
Total current assets		12,772			14,242			11,497			14,242
Operating lease right-of-use assets		262			436			170			436
Property and equipment, net		94			84			96			84
Other assets		475			476			476			476
TOTAL ASSETS	$	13,603		$	15,238		$	12,239		$	15,238

LIABILITIES AND STOCKHOLDERS' EQUITY
Liabilities:
Current liabilities:
Accounts payable	$	208		$	302		$	1,354		$	302
Accrued liabilities		1,883			2,115			1,325			2,115
Operating lease liabilities		298			416			195			416
Total current liabilities		2,389			2,833			2,874			2,833
Operating lease liabilities-non-current		5			87			1			87
Total liabilities		2,394			2,920			2,875			2,920
Commitments & contingencies (please refer to Note 8)
Commitments & contingencies (Note 8)
Stockholders' equity:
Preferred stock: 5,000 shares authorized; none issued and outstanding at June 30, 2021 and December 31, 2020		0			0
Common stock, $0.01 par value; 100,000 and 75,000 shares authorized at June 30, 2021 and December 31, 2020, respectively; 44,615 and 41,782 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively		447			418
Preferred stock: 5,000 shares authorized; none issued and outstanding at September 30, 2021 and December 31, 2020								0			0
Common stock, $0.01 par value; 100,000 and 75,000 shares authorized at September 30, 2021 and December 31, 2020, respectively; 44,943 and 41,782 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively								450			418
Additional paid-in capital		150,202			147,963			150,643			147,963
Accumulated deficit		(139,440	)		(136,063	)		(141,729	)		(136,063	)
Total stockholders' equity		11,209			12,318			9,364			12,318
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	13,603		$	15,238		$	12,239		$	15,238

The accompanying notes are an integral part of these condensed consolidated financial statements.

	Common Stock				Additional Paid-In			Accumulated			Total Stockholders' Equity			Common Stock				Additional Paid-In			Accumulated			Total Stockholders' Equity
	Shares		Amount		Capital			Deficit			(Deficit)			Shares		Amount		Capital			Deficit			(Deficit)
Balance at December 31, 2020		41,782	$	418	$	147,963		$	(136,063	)	$	12,318			41,782	$	418	$	147,963		$	(136,063	)	$	12,318
Net loss		—		0		0			(1,518	)		(1,518	)		—		0		0			(1,518	)		(1,518	)
Stock-based compensation expense related to employee and director stock options		—		0		130			0			130			—		0		130			0			130
Stock-based compensation expense related to non-employee stock options		—		0		53			0			53			—		0		53			0			53
Balance at March 31, 2021		41,782	$	418	$	148,146		$	(137,581	)	$	10,983			41,782	$	418	$	148,146		$	(137,581	)	$	10,983
Net loss		—		0		0			(1,859	)		(1,859	)		—		0		0			(1,859	)		(1,859	)
Issuance of warrants		—		0		13			0			13			—		0		13			0			13
Issuance of common stock, net of offering costs		2,673		27		1,749			0			1,776			2,673		27		1,749			0			1,776
Vesting of employee restricted stock awards		160		2		(2	)		0			0			160		2		(2	)		0			0
Stock-based compensation expense related to employee and director stock options		—		0		242			0			242			—		0		242			0			242
Stock-based compensation expense related to non-employee stock options		—		0		54			0			54			—		0		54			0			54
Balance at June 30, 2021		44,615	$	447	$	150,202		$	(139,440	)	$	11,209			44,615	$	447	$	150,202		$	(139,440	)	$	11,209
Net loss															—		0		0			(2,289	)		(2,289	)
Vesting of employee restricted stock awards															328		3		217			0			220
Stock-based compensation expense related to employee and director stock options															—		0		151			0			151
Stock-based compensation expense related to non-employee stock options															—		0		73			0			73
Balance at September 30, 2021															44,943	$	450	$	150,643		$	(141,729	)	$	9,364

	Common Stock				Additional Paid-In			Accumulated			Total Stockholders' Equity			Common Stock				Additional Paid-In			Accumulated			Total Stockholders' Equity
	Shares		Amount		Capital			Deficit			(Deficit)			Shares		Amount		Capital			Deficit			(Deficit)
Balance at December 31, 2019		27,938	$	279	$	125,718		$	(125,024	)	$	973			27,938	$	279	$	125,718		$	(125,024	)	$	973
Net loss		—		0		0			(1,582	)		(1,582	)		—		0		0			(1,582	)		(1,582	)
Issuance of common stock in connection with exercise of warrants		299		3		198			0			201			299		3		198			0			201
Vesting of employee restricted stock awards		2		0		2			0			2			2		0		2			0			2
Stock-based compensation expense related to employee and director stock options		—		0		45			0			45			—		0		45			0			45
Stock-based compensation expense related to non-employee stock options		—		0		12			0			12			—		0		12			0			12
Balance at March 31, 2020		28,239	$	282	$	125,975		$	(126,606	)	$	(349	)		28,239	$	282	$	125,975		$	(126,606	)	$	(349	)
Net loss		—		0		0			(4,482	)		(4,482	)		—		0		0			(4,482	)		(4,482	)
Issuance of common stock, net of offering costs		5,838		58		5,162			0			5,220			5,838		58		5,162			0			5,220
Issuance of common stock in connection with exercise of warrants		571		6		462			0			468			571		6		462			0			468
Stock-based compensation expense related to employee and director stock options		—		0		92			0			92			—		0		92			0			92
Stock-based compensation expense related to non-employee stock options		—		0		(2	)		0			(2	)		—		0		(2	)		0			(2	)
Stock option modification		—		0		36			0			36			—		0		36			0			36
Balance at June 30, 2020		34,648	$	346	$	131,725		$	(131,088	)	$	983			34,648	$	346	$	131,725		$	(131,088	)	$	983
Net loss															—		0		0			(3,221	)		(3,221	)
Reclassification of warrant liability to equity – see Note 11															—		0		9,293			0			9,293
Issuance of common stock in connection with exercise of warrants, net															6,899		69		6,356			0			6,425
Issuance of RSUs to non-employees for services															193		2		218			0			220
Issuance of stock for option exercises															20		0		6			0			6
Stock-based compensation expense related to employee and director stock options															—		0		142			0			142
Stock-based compensation expense related to non-employee stock options															—		0		17			0			17
Stock option modification															—		0		17			0			17
Balance at September 30, 2020															41,760	$	417	$	147,774		$	(134,309	)	$	13,882

The accompanying notes are an integral part of these condensed consolidated financial statements.

	Six Months Ended June 30,						Nine Months Ended September 30,
	2021			2020			2021			2020

Operating activities:
Net loss	$	(3,377	)	$	(6,064	)	$	(5,666	)	$	(9,285	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		20			28			32			40
Gain on early termination of lease								0			(54	)
(Loss) on disposal of property and equipment								0			(1	)
Stock-based compensation expense for options and stock issued to employees and directors		372			137			523			279
Stock-based compensation expense for options and stock issued to non-employees		107			10			180			27
Stock option modification expense		0			36			0			53
Vesting of employee restricted stock awards		(2	)		2			2			2
Issuance of warrants		13			0			0			0
Issuance of RSU’s to non-employees for services								13			220
Non-cash loss on changes in fair value of warrant liability		0			3,635			0			5,224
Non-cash (gain) on changes in fair value of embedded derivative liability		0			(2	)		0			(3	)
Interest expense related to amortization of debt issuance and debt discount		0			143			0			141
Interest expense related to amortization of debt issuance related to related party notes payable		0			2			0			2
Changes in operating assets and liabilities:
Accounts receivable		(126	)		(498	)		263			(226	)
Inventory		(74	)		(134	)		(361	)		(293	)
Prepaid expenses and other current assets		12			(230	)		(81	)		191
Operating lease right-of-use assets		174			449			266			734
Other assets		(1	)		0			0			1
Accounts payable and accrued liabilities		(326	)		473			262			355
Operating lease liabilities		(200	)		(513	)		(307	)		(784	)
Deferred revenue		2			115
Other current liabilities								0			28
Related party notes payable		0			73			0			73
Long-term obligations		0			432
Net cash used in operating activities		(3,406	)		(1,906	)		(4,874	)		(3,276	)

Investing activities:
Purchases of property and equipment		(27	)		0			(44	)		(5	)
Net cash used in investing activities		(27	)		0			(44	)		(5	)

Financing activities:
Proceeds from common stock issuances, net		1,775			5,220			1,994			5,220
Proceeds from exercise of options								—			6
Proceeds from exercise of warrants		0			669			0			7,094
Payment on the Convertible Note (see Note 10)		0			(1,145	)		0			(1,563	)
Payment on the Promissory Note (see Note 9)		0			(1,000	)		0			(1,000	)
Net cash provided by financing activities		1,775			3,744			1,994			9,757
Net (decrease) increase in cash, cash equivalents, and restricted cash		(1,658	)		1,838			(2,924	)		6,476
Cash, cash equivalents and restricted cash, beginning of year		12,427			7,412			12,427			7,412
Cash, cash equivalents and restricted cash, end of period	$	10,769		$	9,250		$	9,503		$	13,888

The accompanying notes are an integral part of these condensed consolidated financial statements.

NovaBay Pharmaceuticals, Inc. (the “Company”) is a medical device company predominantly focused on eye care. A majority of our revenue comes from Avenova®, an FDA cleared product sold in the United States that has proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from skin around the eye, including the eyelid. Avenova is formulated with our proprietary, stable and pure form of hypochlorous acid. Avenova is available directly to consumers through our online sales channel and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.

We continue to promote Avenova through all four of our primary distribution channels: (1) our over-the-counter direct-to-consumer model, allowing customers to purchase either online or at select brick and mortar stores; (2) retail pharmacies, dispensing Avenova to patients through national pharmacy chains across all 50 states; (3) our Partner Pharmacy Program, providing a consistent patient experience at contracted pricing; and (4) our physician dispensed channel, allowing patients to buy Avenova during office visits to their preferred eye care specialist. ~~We continue to achieve record overall Avenova unit sales quarter over quarter with more people using Avenova than ever before.~~

Avenova was launched as a prescription only product in 2016. To expand our addressable market, we launched Avenova as an over-the-counter product during the second quarter of 2019. By creating a consumer driven product that does not require a doctor’s prescription, we made Avenova available to many more potential customers. Over-the-counter Avenova also capitalizes on a trend to sell over-the-counter pharmaceutical products directly to consumers and adds convenience by allowing customers to forego a time-consuming doctor visit and trip to the pharmacy.

The launch of over-the-counter Avenova online proved to be especially fortuitous during the COVID-19 pandemic as it allowed consumers to order Avenova online without a prescription and without leaving their homes.

Over-the-counter Avenova is now our leading product by unit sales and net revenue despite having a lower average net selling price than ~~prescription Avenova.~~Avenova sold through pharmacy channels. This sales performance reflects our ongoing focus and ~~increasing~~ spend on digital marketing, social media and public relations initiatives to promote Avenova directly to the end consumer. Avenova is available on Amazon.com, Walmart.com, and Avenova.com. Beginning in February 2021, Avenova became available at CVS store locations throughout the U.S. and on CVS.com, one of the nation’s largest retail chains.

Although we expect the online sales channel to continue to be our fastest-growing channel, support for Avenova from the medical community is important to maintaining its reputation as a preferred product. The “doctor recommended” halo effect around our brand remains strong due in part to our continued promotion of prescription Avenova.

Earlier this year, we launched a rebranded CelleRx® into the beauty industry as CelleRx® Clinical Reset™. ~~Prior to this rebranding, our marketing of CelleRx focused on medical professionals only.~~ Clinical Reset is formulated with NovaBay’s patented, pure, prescription-grade hypochlorous acid, a naturally occurring oxidant that is also produced by white blood cells within the human body. It keeps the skin’s natural barrier intact, which when out of balance can allow acne, rosacea and infection to set in. Clinical Reset is complementary to a daily beauty regime for use on clean skin or over makeup. With the rebranding, we are leveraging new consumer focused messaging and the product’s pharmaceutical pedigree in robust social media and print advertising campaigns marketing CelleRx Clinical Reset in the beauty industry.

Beyond Avenova and CelleRx, we have developed additional products containing our proprietary, stable and pure form of hypochlorous acid, including NeutroPhase® and PhaseOne® for the wound care market. NeutroPhase is only sold in China through our exclusive distributor, Pioneer Pharma Co. Ltd. PhaseOne is only sold in the United States through our exclusive distributor, PhaseOne Health, LLC.

Last year, we responded to the national need for protective personal equipment (“PPE”) by tapping into our international supply network and launching the sale of third-party manufactured disposable KN95 facial coverings (“KN95 Masks”) and other PPE. Although sales from the KN95 Masks were significant in the second quarter of 2020, we subsequently experienced a significant decrease in PPE sales ~~in the~~ ~~third~~ ~~and~~ ~~fourth~~ ~~quarters of~~ ~~2020~~ as supply shortages narrowed, prices declined and distribution competition increased. We have returned our focus to our core business in eyecare and we do not anticipate dedicating significant future Company resources toward the sale of PPE and we do not expect significant future revenue from PPE sales.

During the second quarter of this year, we introduced two complementary products to support the use of Avenova. Our Warm Eye Compress not only provides effective heat therapy for many eye conditions, but it also improves Avenova’s ability to restore the eyes’ natural defenses against tear evaporation. Additionally, the i-Chek Illuminated Eye Examination Mirror (“~~i-chek”~~i-Chek”) allows Avenova customers to get a closer look at common eye conditions that are often of concern to Avenova customers. These eye conditions include blepharitis, chalazion and styes. The i-Chek also helps Avenova users who suffer from dry eye to identify dirt, oil or debris that need to be removed from the eyelids and eyelashes for optimum ocular health. The use of Avenova and both products is meant to provide Avenova customers with a holistic approach to lid and lash hygiene.

Based ~~primarily~~ on our funds available on ~~June~~September 30, 2021, as well as the proceeds from the Company’s private placement of its Series B Non-Voting Convertible Preferred Stock and common stock warrants that was completed on November 2, 2021, management believes that the Company’s existing cash and cash equivalents and cash flows generated from product sales will be sufficient to enable the Company to meet its planned operating expenses at least through ~~August~~November 12, ~~2022.~~2022, including the cost to acquire and integrate DERMAdoctor. See Note 18, “DERMAdoctor LLC Transaction”. However, changing circumstances may cause the Company to expend cash significantly faster than currently anticipated, and the Company may need to spend more cash than currently expected because of circumstances beyond its control. Additionally, our future results, cash expenditures and ability to obtain additional external financing could be adversely affected by the COVID-19 pandemic and general adverse economic conditions.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and are expressed in U.S. dollars.

The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include contract liabilities related to product sales, useful lives for property and equipment and related depreciation calculations, assumptions for valuing options and warrants, income taxes and other contingencies. Actual results could differ from those estimates.

The accompanying unaudited interim condensed consolidated financial statements and related disclosures have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented.

The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period.

The financial statements and notes included herein should be read in conjunction with the annual financial statements and notes for the year ended December 31, 2020, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on March 25, 2021.

The Company considers all highly-liquid instruments with a stated maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are stated at cost, which approximates fair value. As of ~~June~~September 30, 2021 and December 31, 2020, the Company’s cash and cash equivalents were held in a highly-rated, major financial institution in the United States.

The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets that sum to the total of the same reported in the condensed consolidated statements of cash flows (in thousands):

The restricted cash amount included in other assets on the condensed consolidated balance sheets represents amounts held as certificates of deposit for Company credit cards and lease arrangements as contractually required by our financial institution and landlord.

Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a highly-rated, major financial institution in the United States.

Deposits in this bank may exceed the amount of federal insurance provided on such deposits. The Company does not believe it is exposed to significant credit risk due to the financial position of the financial institution in which the deposits are held.

During the three and ~~six~~nine months ended ~~June~~September 30, 2021 and 2020,Company revenues were derived primarily from sales of Avenova. During the ~~three~~ ~~and~~ ~~six~~nine months ended ~~June 30,~~ 2020,revenues during the second quarter of that period were derived primarily from sales of KN95 Masks ~~and Avenova.~~in response to the national need for PPE.

During the three and ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, revenues from each product were as follows (in thousands):

During the three months ended ~~June~~September 30, 2021 and 2020, sales of Avenova via Amazon comprised ~~52%~~55% and ~~42%~~47% of total Avenova net revenue, respectively. During the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, sales of Avenova via Amazon comprised ~~58%~~57% and 46% of total Avenova net revenue, respectively. No other individual distributor comprised greater than 10% of total Avenova net revenue during the three and ~~six~~nine months ended ~~June~~September 30, 2021 and 2020.

As of ~~June~~September 30, 2021 and December 31, 2020, accounts receivable from our major distribution partners greater than 10% were as follows:

The Company relies on two contract manufacturers to produce its products. The Company does not own any manufacturing facilities and intends to continue to rely on third parties for the supply of finished goods. Contract manufacturers may or may not be able to meet the Company’s needs with respect to timing, quantity or quality. In particular, it is possible that we may suffer from unexpected supply chain delays in light of the ongoing COVID-19 pandemic.

The Company’s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities. The Company’s cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.

The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures, with respect to assets and liabilities that are measured at fair value on a recurring basis and nonrecurring basis. Under this standard, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The standard also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. There are three levels of inputs that may be used to measure fair value:

Level 1 – quoted prices in active markets for identical assets or liabilities;

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable; and

Level 3 – inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).

Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identifies amounts due that are in dispute and it believes are unlikely to be collected. At ~~June~~September 30, 2021 and December 31, 2020, management recorded 0 reserve for accounts receivable.

Inventory is comprised of (1) raw materials and supplies, such as bottles, packaging materials, labels, boxes and pumps; (2) goods in progress, which are normally filled but unlabeled bottles; and (3) finished goods. We utilize contract manufacturers to produce our products and the price paid to these manufacturers is included in inventory. Inventory is stated at the lower of cost or estimated net realizable value determined by the first-in, first-out method. At both ~~June~~September 30, 2021 and December 31, 2020, management had recorded an allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments of $0.1 million and $0.2 ~~million.~~million, respectively.

Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five to seven years for office equipment, three years for computer equipment and software, and seven years for furniture and fixtures. Leasehold improvements are amortized over the lease term.

The costs of normal maintenance, repairs, and minor replacements are expensed as incurred.

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid or incentives received.

The Company has elected to combine lease and non-lease components as a single component for all leases in which it is a lessee or a lessor. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. As a result, as of the effective date, the Company no longer recognizes deferred rent on the consolidated balance sheets.

ASC 220, Comprehensive Income, requires that an entity's change in equity or net assets during a period from transactions and other events from non-owner sources be reported.

Revenue generated through the Company’s webstores, Avenova.com and CelleRx.com, for Avenova and CelleRx (as well as the KN95 Masks) is recognized upon fulfillment, which generally occurs upon delivery of the related products to multiple third-party carriers. Shipping and handling costs are expensed as incurred and included in cost of goods sold in the consolidated statements of operations and comprehensive loss. We present revenue net of sales taxes and refunds.

Revenue generated through Amazon.com and Walmart.com is recognized upon fulfillment, which generally occurs upon delivery of the related products to a third-party carrier. We present revenue net of commissions and any related fulfillment and shipping fees charged by these partners. Fees paid to partners for promoting our products are expensed as incurred and are included in sales and marketing expenses within the operating expenses in the consolidated statements of operations and comprehensive loss.

The Company also generates Avenova product revenue through product sales to its major distribution partners. Product supply of Avenova is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon receipt by the distributor on a “sell-in” basis. Upon recognition of product sales, contract liabilities are recorded for invoiced amounts that are subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, and product returns. The Company derives its rate of return from historical data and updates its return rate assumption quarterly. Payment for product supply is typically due 30 days after control transfers to the distributor.

~~ated~~generated through the Company’s partner pharmacies is recognized when control of the product transfers to the end customer. Revenue for product sales to CVS is recognized upon transfer of control to CVS, which generally occurs upon delivery of the related products to a third-party carrier, net of estimated future product returns.

Cost of goods sold includes third-party manufacturing costs, shipping and handling costs, and other costs associated with products sold. Cost of goods sold also includes any necessary allowance for excess and obsolete inventory along with lower of cost and estimated net realizable value.

The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities, including submissions to the Food and Drug Administration (“FDA”).

Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss.

Advertising costs are expensed in the period in which the costs are incurred. Advertising expenses were ~~$0.7~~$0.8 million and ~~$0.3~~$0.5 million for the three months ended ~~June~~September 30, 2021 and 2020, respectively. Advertising expenses were ~~$1.5~~$2.3 million and ~~$0.7~~$1.3 million for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, respectively.

The Company’s stock-based compensation includes grants of stock options and restricted stock units (“RSUs”) to employees, consultants and non-employee directors. The expense associated with these grants is recognized in the Company’s condensed consolidated statements of stockholders’ equity (deficit) based on their fair values as they are earned under the applicable vesting terms. For stock options granted, the fair value of the stock options is estimated using a Black-Scholes option pricing model. See Note 13, “Equity-Based Compensation” for further information regarding stock-based compensation expense and the assumptions used in estimating that expense. The Company accounts for RSUs issued to employees and non-employees (board members and consultants) based on the fair market value of the Company’s common stock as of the date of issuance.

The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized.

The Company accounts for common stock purchase warrants issued in connection with its equity offerings in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging.

The Company accounts for common stock purchase warrants issued in connection with share-based compensation arrangements in accordance with the provisions of ASC 718, Stock Compensation, which encompasses the provisions of ASC 480, Distinguishing Liabilities from Equity.

The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). Additionally, for common stock purchase warrants accounted for in accordance with ASC 718, Stock Compensation, the Company classifies as liabilities any contracts where it believes the warrants are deemed to be probable of issuance.

For warrants that are classified as liabilities, the Company records the fair value of the warrants at each balance sheet date and records changes in the estimated fair value as a non-cash gain or loss in the consolidated statements of operations and comprehensive loss. The fair values of these warrants are determined using the Black-Scholes option pricing model, the Binomial Lattice (“Lattice”) valuation model, or the Monte Carlo simulation model where deemed appropriate. These values are subject to a significant degree of management’s judgment.

The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (“EPS”).

Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods because their effect would be anti-dilutive.

~~During~~We have incurred a net loss for all periods presented in the ~~three~~unaudited condensed consolidated statements of operations and ~~six~~ ~~months ended~~ ~~June 30, 2021~~ ~~and~~ ~~2020,~~ ~~there was~~ no ~~difference between basic and diluted EPS in each period due to the Company’s net~~comprehensive loss.

The following ~~table sets forth~~common stock equivalents were not included in the ~~calculation~~computation of ~~basic EPS and diluted EPS (in thousands, except~~net loss per share ~~amounts):~~

~~The following outstanding stock options and stock warrants were excluded from the diluted EPS computation as~~because their effect would ~~have been~~be anti-dilutive (in thousands):

For information regarding recent accounting pronouncements that could affect our business, results of operations, financial condition, and liquidity, see Note 2, “Summary of Significant Accounting Policies” included in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on March 25, 2021.Since that date and as of the date of this report, there has been no change to management’s expectations about the potential impact of recent accounting pronouncements.

The Company’s cash equivalents are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. The types of investments that are generally classified within Level 1 of the fair value hierarchy include money market securities and certificates of deposit.

The following table presents the Company’s assets measured at fair value on a recurring basis as of ~~June~~September 30, 2021 (in thousands):

The following table presents the Company's assets measured at fair value on a recurring basis as of December 31, 2020 (in thousands):

There were no liabilities measured at fair value on a recurring basis as of ~~June~~September 30, 2021 or December 31, 2020.

Prepaid expenses and other current assets consisted of the following (in thousands):

Depreciation and amortization expense was ~~$11~~$13 thousand and ~~$14~~$12 thousand for the three months ended ~~June~~September 30, 2021 and 2020, respectively, and ~~$20~~$32 thousand and ~~$28~~$40 thousand for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, respectively.

As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may enable it to recover a portion of any future payments. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, it has not recorded any liabilities for these agreements as of ~~June~~September 30, 2021.

In the normal course of business, the Company provides indemnification of varying scope under its agreements with other companies, typically its clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, it generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with the use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third party with respect to its products. The term of these indemnification agreements is generally perpetual. The potential future payments the Company could be required to make under these indemnification agreements is unlimited. Historically, costs related to these indemnification provisions have been immaterial. The Company also maintains various liability insurance policies that limit its exposure. As a result, it believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements as of ~~June~~September 30, 2021.

On July 29, 2019, Mr. John McGovern, the Company’s former Interim President & Chief Executive Officer and Chief Financial Officer, submitted a demand for arbitration in connection with his separation from service with the Company. The arbitration was settled in December 2020. Mr. McGovern released the Company from all outstanding obligations upon settlement.

The Company’s insurance carrier determined that the Company was entitled to a $0.3 million reimbursement for litigation costs incurred in conjunction with the McGovern matter. The Company received a $0.3 million reimbursement on April 23, 2021 which was offset against general and administrative expenses in the Company’s Consolidated Statement of Operation and Comprehensive Loss for the three months ended March 31, 2021.

As of ~~June~~September 30, 2021, there were no other matters that, in the opinion of management, would ultimately result in liability that would have a material adverse effect on the Company’s financial position, results of operations or cash flows.

The Company leases office space for its corporate headquarters located in Emeryville, California. The initial lease term is through February 28, 2022. The Company has the option to extend the term of the lease for one five (5)-year period upon written notice to the landlord. The Company intends to exercise the renewal option for this lease.

The Company also had a lease commitment for laboratory facilities and office space at EmeryStation North in Emeryville, California (“EmeryStation”) under an operating lease. In July 2016, the Company subleased the EmeryStation space (the “Sublease Agreement”). The Sublease Agreement commenced September 8, 2016. The EmeryStation lease and Sublease Agreement were terminated as of August 31, 2020 pursuant to a sublease termination agreement executed on July 31, 2020.

The components of lease expense for the three and ~~six~~nine months ended ~~June~~September 30, 2021 and 2020 were as follows (in thousands):

The Company has measured its operating lease liabilities at its incremental borrowing rate over the remaining term for each operating lease. The weighted average remaining lease term and the weighted average discount rate are summarized as follows:

Future lease payments under non-cancelable leases as of ~~June~~September 30, 2021 were as follows (in thousands):

On ~~May 13, 2020,~~ the Company entered into an agreement with TLF Bio Innovation Lab LLC (“TLF Bio Innovation”) to manage the relaunch of the Company’s CelleRx product (the “TLF Agreement”) which was further amended on ~~September 4, 2020~~ ~~and subsequently terminated on~~ ~~February 4, 2021.~~ ~~TLF Bio Innovation was granted warrants exercisable for 15,000 shares of the Company’s common stock with an exercise price of $0.6718 on~~ ~~January 15, 2021.~~

On ~~April 16, 2020,~~ the Company entered into an international distribution agreement with Shenzhen Microprofit Biotech Co., Ltd. (“Microprofit”) (the “Microprofit Agreement”). In accordance with the Microprofit Agreement, the Company assisted Microprofit in applying for approval of Microprofit’s SARS-CoV-2 IgG and IgM Antibody Combined Test Kit (“Test Kits”) by the FDA. Under the terms of the Microprofit Agreement, if such approvals were granted, the Company would issue warrants to certain Microprofit officers exercisable for an aggregate number of shares of the Company’s common stock equivalent to 12% of the Company’s outstanding common stock on the date of approval. If FDA approval were received, the Microprofit Agreement would grant the Company exclusive rights to distribute the Test Kits in the United States through ~~December 31, 2021.~~ ~~As of~~ ~~June 30, 2021,~~ ~~the Company determined that the issuance of warrants under the Microprofit Agreement is~~ ~~not~~ ~~probable. Accordingly, the parties mutually agreed to terminate the agreement subsequent to~~ ~~June 30, 2021~~ on ~~August 10, 2021.~~

~~In connection with the Microprofit Agreement, on~~ ~~April 16, 2020,~~ ~~the Company entered into an intermediary distribution agreement with Chongqing Pioneer Pharma Holdings Limited (“Chongqing Pioneer”), a related party, which was subsequently amended on~~ ~~June 29, 2020 (~~the “Distribution Agreement”). The Distribution Agreement provided that the Company will purchase all Test Kits from Chongqing Pioneer as an intermediary. The Distribution Agreement was terminated subsequent to ~~June 30, 2021~~ on ~~August 10, 2021.~~

On February 27, 2019, the Company issued a $1.0 million promissory note payable to Pioneer Pharma (Hong Kong) Company Ltd. (“Pioneer Pharma”), which was amended on ~~June~~September 25, 2019 and May 14, 2020 (the “Promissory Note”). The Promissory Note provided for an interest payment of $0.2 million which was initially amended to a payment of $0.3 million and subsequently amended to replace the cash interest payment with the delivery of 65,178 units of NeutroPhase (40ml) to Pioneer Pharma. The second amendment to the Promissory Note also provided the Company with the right to repay the note at any time. On May 14, 2020, the Company repaid the $1.0 million principal balance of the Promissory Note using proceeds raised through the at-the-market offering and equity program (“ATM Program”) (see Note 12, “Stockholders’ Equity”). The Company settled the accrued interest through two separate shipments of NeutroPhase in 2020. Upon full repayment of principal and interest during the year ended December 31, 2020, the Company was released from the Promissory Note with Pioneer Pharma.

In connection with the Promissory Note, the Company paid China Kington a 2% fee for brokering the transaction and entered into a consulting agreement with China Kington for a term of one year, which expired on March 1, 2020 (the “Consulting Agreement”). Bob Wu, acting in a dual role as a member of the Company’s Board of Directors (the “Board”) and as principal of China Kington, was paid $0.1 million pursuant to the Consulting Agreement. Upon the expiration of the Consulting Agreement, the parties entered into a new consulting agreement, in which no cash compensation will be paid. Debt issuance costs associated with the issuance of the Promissory Note of $20 thousand was recognized and recorded as an offset to the related party note payable in the consolidated balance sheets.

The interest expense recognized, including amortization of the issuance costs, was ~~$27 thousand~~$0 and $75 thousand during the three and ~~six~~nine months ended ~~June~~September 30, 2020, respectively. There was 0 comparable expense during the three and ~~six~~nine months ended ~~June~~September 30, 2021.

On March 26, 2019, the Company entered into a Securities Purchase Agreement with Iliad Research and Trading, L.P. (the “Lender”), pursuant to which the Company issued a Secured Convertible Promissory Note (the “Convertible Note”) to the Lender dated as of March 26, 2019. The Convertible Note had an original principal amount of $2.2 million, bore interest at a rate of 10% per annum and matured on September 26, 2020, unless earlier paid, redeemed or converted in accordance with its terms. The Company received net proceeds of $2.0 million after deducting an original issue discount of $0.2 million and debt issuance cost of Lender’s transaction fees of $15 thousand. The Company recognized an additional $0.2 million of debt issuance costs associated with the issuance of the Convertible Note. The Convertible Note was repaid in full during the third quarter of 2020. Upon full repayment, the Company was released from the Iliad Securities Purchase Agreement with Lender.

During the three and ~~six~~nine months ended ~~June 30, 2020,~~ ~~the Company recorded a gain of $0 and $2 thousand, respectively, in the unaudited condensed consolidated statements of operations and comprehensive loss. There was 0 comparable gain or loss during the~~ ~~three~~ ~~and~~ ~~six~~ ~~months ended~~ ~~June 30, 2021.~~

~~During both the~~ ~~three~~ ~~and~~ ~~six~~ ~~months ended~~ ~~June~~September 30, 2020, the effective interest rate on the Convertible Note was ~~37%~~22% and ~~43%~~20%, respectively. Interest expense recognized, including amortization of the issuance costs and debt discount, was ~~$59~~$16 thousand and ~~$199~~$215 thousand during the three and ~~six~~nine months ended ~~June~~September 30, 2020, respectively. There was 0 comparable expense during the three and ~~six~~nine months ended ~~June~~September 30, 2021.

The Company issued the July 2011 Warrants (as defined in Note 12, “Stockholders’ Equity”) in the third quarter of 2011. The terms of the July 2011 Warrants required registered shares to be delivered upon warrant exercise and potential cash-settlement in the event of a specified fundamental transaction. Under ASC 480, Distinguishing Liabilities from Equity, the warrants were classified as liabilities because the Company’s potential obligation to deliver registered shares and cash-settle the warrants were deemed to be beyond the Company’s control. The fair value of outstanding July 2011 Warrants was determined at each reporting date using a Lattice model with changes in fair value recorded in the consolidated statements of operations and comprehensive loss.

On March 6, 2020, the remaining 35,107 July 2011 Warrants expired unexercised. There were 0 July 2011 Warrants outstanding as of ~~June~~September 30, 2021.

The Company issued the October 2015 Warrants (as defined in Note 12, “Stockholders’ Equity”) in the third quarter of 2015. The terms of the October 2015 Warrants required potential cash-settlement in the event of a specified fundamental transaction. Under ASC 480, Distinguishing Liabilities from Equity, the warrants were classified as liabilities because the Company’s potential obligation to cash-settle the warrants was deemed to be beyond the Company’s control. The fair value of outstanding October 2015 Warrants was determined at each reporting date using a Lattice model with changes in fair value recorded in the consolidated statements of operations and comprehensive loss.

During the fourth quarter of 2020, a total of 22,680 October 2015 Warrants were exercised, resulting in gross proceeds of $5 thousand. The liability associated with these warrants was adjusted to fair value of $12 thousand as of the date of exercise, with the change in fair value recorded in the consolidated statements of operations and comprehensive loss. The fair value was then transferred to equity.

On October 27, 2020, 15,320 October 2015 expired unexercised. There were 0 October 2015 Warrants outstanding as of ~~June~~September 30, 2021.

As further described in Note 12, “Stockholders’ Equity”, the Company issued the 2019 Domestic Warrants, the 2019 Foreign Warrants and the 2019 Ladenburg Warrants in the third quarter of 2019. The terms of the 2019 Domestic Warrants, 2019 Foreign Warrants and 2019 Ladenburg Warrants all required potential cash-settlement in the event of a specified fundamental transaction. Under ASC 480, Distinguishing Liabilities from Equity, the warrants were classified as liabilities because the Company’s potential obligation to cash-settle the warrants was deemed to be beyond the Company’s control. The fair value of outstanding warrants was determined at each reporting date using a Black-Scholes option pricing model with the changes in fair value recorded in the consolidated statements of operations and comprehensive loss.

Upon issuance in the third quarter of 2019, the fair value of the 2019 Domestic Warrants, 2019 Foreign Warrants and 2019 Ladenburg Warrants was determined to be $3.1 million, $2.0 million and $0.1 million, respectively.

In the third quarter of 2020, as further described in Note 12, “Stockholders’ Equity”, the 2019 Domestic Warrants and 2019 Foreign Warrants were exercised at reduced exercise prices. The warrant liabilities associated with these warrants was adjusted to their fair values as of the date of exercise, with the change in fair values recorded in the consolidated statements of operations and comprehensive loss. The fair values were then transferred to equity. As of the date of exercise, the fair value of the 2019 Domestic Warrants and 2019 Foreign Warrants was determined to be $4.9 million and $4.2 million, respectively, in accordance with the following key assumptions:

There were 0 2019 Domestic Warrants or 2019 Foreign Warrants outstanding as of ~~June~~September 30, 2021.

In the third quarter of 2020, as further described in Note 12, “Stockholders’ Equity”, the Company amended the 2019 Ladenburg Warrants. The Company’s potential obligation to cash-settle the warrants if a specified fundamental transaction occurred was amended to apply only in situations within the Company’s control. Pursuant to this change, the 2019 Ladenburg Warrants were no longer classified as liabilities. The warrant liability associated with these warrants was adjusted to fair value as of the date of the amendment, with the change in fair value recorded in the consolidated statements of operations and comprehensive loss. The fair value was then transferred to equity. The fair value of the 2019 Ladenburg Warrants was determined to be $0.2 million on the date of amendment in accordance with the following key assumptions:

The 2019 Ladenburg Warrants will no longer be adjusted to fair value in reporting periods after the amendment. All 2019 Ladenburg Warrants remained outstanding as of ~~June~~September 30, 2021.

The Company is authorized to issue up to 5,000,000 shares of preferred stock with rights and preferences as may be approved by its Board of Directors under its Amended and Restated Certificate of Incorporation. There were 0 shares of preferred stock outstanding as of ~~June~~September 30, 2021 and December 31, 2020.

In the second quarter of 2020, the Company established the 2020 ATM Program with Ladenburg Thalmann & Co. Inc. (“Ladenburg”). For additional information regarding the offering and equity program, see the Company’s Current Reports on Form 8-K filed with the SEC on April 27, 2020 and ~~June~~September 15, 2020. During the second quarter of 2020, 5,836,792 shares of common stock were issued under the 2020 ATM Program for total net proceeds of $5.6 million, net of offering costs of $0.4 million.

In the second quarter of 2021, the Company established the 2021 ATM Program with Ladenburg. For additional information regarding the offering and equity program, see the Company’s Current Report on Form 8-K filed with the SEC on May 14, 2021. During the second quarter of 2021, 2,672,000 shares of common stock were issued under the 2021 ATM Program for total net proceeds of $1.8 million, net of offering costs of $0.1 million.

On ~~May 13, 2020,~~ ~~TLF Bio Innovation purchased 1,000 shares of the Company’s common stock for total proceeds of $1 thousand pursuant to the TLF Agreement described in Note~~ 8, ~~“Commitments and Contingencies”.~~

In the third quarter of 2011, the Company issued 139,520 common stock purchase warrants exercisable for 139,520 shares of common stock in connection with a registered direct financing (the “July 2011 Warrants”). The July 2011 Warrants were issued with an exercise price of $33.25 and an expiration date of July 5, 2016. In October 2015, in connection with a separate financing event, the exercise price of outstanding July 2011 Warrants was reduced to $5.00 per share and the expiration date extended to March 6, 2020. In February 2016 and May 2019, the exercise price of outstanding July 2011 Warrants was reduced to $1.81 and $0.2061 per share, respectively, pursuant to price protection provisions of the warrants.

In March 2020, a total of 35,107 July 2011 Warrants expired unexercised. As of ~~June~~September 30, 2021, there were 0 July 2011 Warrants outstanding.

In the first quarter of 2015, the Company issued 649,133 common stock purchase warrants exercisable for 649,133 shares of common stock in connection with a private placement offering (the “March 2015 Warrants”). The exercise price of individual March 2015 Warrants varied between $15.00 and $16.25 per share at the time of issuance. The Company issued 278,200 of the March 2015 Warrants with an expiration date of March 6, 2020 and the remaining 370,933 March 2015 Warrants with an expiration date of ~~June~~September 6, 2015. In October 2015, in connection with a separate financing event, the exercise price of all outstanding March 2015 Warrants was reduced to $5.00 per share and the expiration date of all outstanding warrants expiring on ~~June~~September 6, 2015 was extended to March 6, 2020. In February 2016 and May 2019, the exercise price of all outstanding July 2011 Warrants was reduced to $1.81 and $0.2061 per share, respectively, pursuant to price protection provisions of the warrants.

During the first quarter of 2020, a total of 70,000 March 2015 Warrants were exercised, resulting in gross proceeds of $14 thousand. Also in the first quarter of 2020, all remaining 7,419 March 2015 Warrants expired unexercised. As of ~~June~~September 30, 2021, there were 0 March 2015 Warrants outstanding.

In the fourth quarter of 2015, the Company issued 442,802 common stock purchase warrants exercisable for 442,802 shares of common stock in connection with a public offering (the “October 2015 Warrants”). The warrants were issued with an exercise price of $5.00 and an expiration date of October 27, 2020. In February 2016 and May 2019, the exercise price of outstanding October 2015 Warrants was reduced to $1.81 and $0.2061 per share, respectively, pursuant to price protection provisions of the warrants. Also during the fourth quarter of 2020, a total of 22,680 October 2015 Warrants were exercised, resulting in gross proceeds of $5 thousand.

During the fourth quarter of 2020, all remaining 15,320 October 2015 Warrants expired unexercised. As of ~~June~~September 30, 2021, there were 0 October 2015 Warrants outstanding.

During the second quarter of 2019, the Company entered into a private placement agreement to sell 1,371,427 shares of common stock and 1,371,427 common stock purchase warrants exercisable for 1,371,427 shares of common stock (the “June 2019 Warrants”) for an aggregate subscription price of $2.4 million. Three accredited investors, Messrs. Xiao Rui Liu, Hai Dong Pang and Ping Huang, subscribed to the private placement for $1.0 million, $0.4 million and $1.0 million, respectively. China Kington served as placement agent in exchange for a commission equal to six percent (6%) of the gross proceeds, totaling $0.1 million. The Company also paid other offering costs of $27 thousand.

The June 2019 Warrants were issued with an exercise price of $0.87 and an expiration date of June 17, 2020. The June 2019 Warrants were callable by the Company if the closing price of the Company’s common stock, as reported on the NYSE American, was $1.00 or greater.

During the first quarter of 2020, a total of 228,571 June 2019 Warrants were exercised, resulting in gross proceeds of $199 thousand. The Company paid China Kington a fee of $12 thousand, or six percent (6%) of the gross proceeds, for brokering the exercise transaction.

During the second quarter of 2020, a total of 571,428 June 2019 Warrants were exercised, resulting in gross proceeds of $497 thousand. The Company paid China Kington a fee of $29 thousand, or six percent (6%) of the gross proceeds, for brokering the exercise transaction. Also during the second quarter of 2020, all remaining 571,428 June 2019 Warrants expired unexercised. As of ~~June~~September 30, 2021, there were 0 June 2019 Warrants outstanding.

August 2019 Common Stock Purchase Agreement, 2019 Domestic Warrants, 2019 Ladenburg Warrants and 2019 Foreign Warrants

In the third quarter of 2019, the Company entered into a purchase agreement (the “2019 Purchase Agreement”) for the sale of (i) 4,198,566 shares of common stock and (ii) 4,198,566 common stock purchase warrants exercisable for 4,198,566 shares of common stock (the “2019 Domestic Warrants”) for gross proceeds of $4.2 million. The 2019 Domestic Warrants were issued with an exercise price of $1.15 and an expiration date of February 13, 2025.

The Company allocated the proceeds between the common stock and 2019 Domestic Warrants by applying the relative fair value allocation methodology. The Company first allocated $3.1 million to the 2019 Domestic Warrants, with the residual amount allocated to the common stock. See Note 11, “Warrant Liability” for further discussion of the key assumptions used to value the 2019 Domestic Warrants.

Ladenburg served as the placement agent for the transaction in exchange for a commission representing six percent (6%) of the gross proceeds, totaling $0.3 million, and 167,942 common stock purchase warrants exercisable for 167,942 shares of common stock with an exercise price of $1.25 per share and an expiration date of August 8, 2024 (the “2019 Ladenburg Warrants”). In addition, the Company reimbursed the Placement Agent $60 thousand for certain expenses. The Company also incurred and paid other offering costs of $0.3 million.

The Company incurred total issuance costs of $0.5 million in conjunction with the 2019 Purchase Agreement. The Company allocated $0.2 million of the issuance costs to the warrant liability which was expensed in the Company’s consolidated statements of operations and comprehensive loss during the period. The remaining $0.3 million was recorded as a reduction of additional paid-in capital in the Company’s consolidated balance sheets. As the 2019 Ladenburg Warrants were accounted for as a stock issuance cost, $59 thousand was allocated to the warrant liability and expensed during the period and $65 thousand was recorded as a reduction to additional paid-in capital in the Company’s consolidated balance sheets. See Note 11, “Warrant Liability” for a discussion of the key assumptions used to value the 2019 Ladenburg Warrants.

During the third quarter of 2020, the Company and the holders of the 2019 Domestic Warrants and the 2019 Foreign Warrants entered into exercise agreements which resulted in the cash exercise of the warrants at a reduced exercise price of $0.99. The Company received aggregate gross proceeds of approximately $6.8 million from the exercises. The Company incurred and paid other offering costs of $0.2 million. The Company also incurred and paid a $0.2 million fee to China Kington for brokering the transaction, which equaled six percent (6%) of the gross proceeds from the 2019 Foreign Warrants.

During the third quarter of 2020, the Company and all holders of the 2019 Domestic Warrants and 2019 Foreign Warrants entered into warrant repricing letter agreements. Pursuant to the agreement, in consideration for the exercise in full of the 2019 Domestic Warrants and 2019 Foreign Warrants, the Company agreed to: (1) reduce the exercise price of the 2019 Domestic Warrants and the 2019 Foreign Warrants to $0.99 per share prior to exercise, and (2) in a private placement, issue new common stock purchase warrants (the “New Warrants”) to purchase up to a number of shares of common stock, equal to 100% of the number of 2019 Domestic Warrants and 2019 Foreign Warrants currently held by such holders upon the holders exercising their warrants.

The New Warrants became exercisable ~~six~~nine months after their issuance, for an aggregate of 6,898,566 shares of common stock. The New Warrants have an exercise price of $1.65 per share and will expire five and a half years after their issuance. The Company determined that the common stock issued from the exercise of the 2019 Domestic and 2019 Foreign Warrants, and the New Warrants to be one unit of account, and therefore did not allocate the proceeds between the common stock and the New Warrants as, the proceeds, even if allocated, would be both recognized in additional paid-in capital.

During the third quarter of 2020, the Company also entered into a reprice agreement with Ladenburg which reduced the exercise price to $0.99 per share and amended certain terms of the 2019 Ladenburg Warrants. The Company’s potential obligation to cash-settle the warrants if a specified fundamental transaction occurred was amended to apply only in situations within the Company’s control. As further described in Note 11, “Warrant Liability”, the 2019 Ladenburg Warrants were no longer classified as a liability as a result of this amendment.

On January 15, 2021, TLF Bio Innovation was granted warrants exercisable for 15,000 shares of the Company’s common stock with an exercise price of $0.6718 (the “TLF Warrants”) ~~pursuant to the TLF Agreement described in Note~~ 8, ~~“Commitments and Contingencies”~~. The TLF Warrants will expire five years after their issuance. The TLF Warrants are classified as equity.

The details of all outstanding warrants as of ~~June~~September 30, 2021 were as follows:

In October 2007, the Company adopted the 2007 Omnibus Incentive Plan (the “2007 Plan”) to provide for the granting of equity awards, such as stock options, unrestricted and restricted common stock, stock units, dividend equivalent rights, and stock appreciation rights to employees, directors and outside consultants, as determined by the Board. The 2007 Plan expired on March 15, 2017. Upon expiration, new awards cannot be issued pursuant to the 2007 Plan, but outstanding awards continue to be governed by its terms. Stock options granted under the 2007 Plan expire no later than ten years from the date of grant. All stock options outstanding under the 2007 Plan were fully vested as of December 31, 2020.

In March 2017, the Company adopted the 2017 Omnibus Incentive Plan (the “2017 Plan”), which was approved by stockholders on June 2, 2017, to provide for the granting of equity awards, such as nonqualified stock options (“NQSOs”), incentive stock options (“ISOs”), restricted stock, performance shares, stock appreciation rights (“SARs”), RSUs and other share-based awards to employees, directors, and consultants, as determined by the Board. The 2017 Plan does not affect awards previously granted under the 2007 Plan. Upon adoption, the 2017 Plan allowed for awards of up to 2,318,486 shares of the Company’s common stock, plus an automatic annual increase in the number of shares authorized for awards on the first day of each of the Company’s fiscal years beginning January 1, 2018 through January 1, 2027 equal to (i) 4% of the number of shares of common stock outstanding on the last day of the immediately preceding fiscal year or (ii) such lesser number of shares of common stock than provided for in Section 4(a)(i) of the 2017 Plan as determined by the Board. On January 15, 2021, the number of shares available for future awards under the 2017 Plan was increased by 1,671,303 shares. As of ~~June~~September 30, 2021, there were ~~2,751,227~~2,325,118 shares available for future awards under the 2017 Plan.

Under the terms of the 2017 Plan, the exercise price of NQSOs, ISOs and SARs may not be less than 100% of the fair market value of the common stock on the date of grant and, if ISOs are granted to an owner of more than 10% of the Company’s stock, then not less than 110% of the fair market value of the common stock on the date of grant. The term of awards will not be longer than ten years, or in the case of ISOs, not longer than five years with respect to holders of more than 10% of the Company’s stock. Stock options granted to employees generally vest over four years, while options granted to directors and consultants typically vest over a shorter period, subject to continued service. The Company issues new shares to satisfy option exercises under the 2007 Plan and the 2017 Plan.

The following table summarizes information about the Company’s stock options and restricted stock outstanding at ~~June~~September 30, 2021 and activity during the period ended ~~June~~September 30, ~~2021:~~2021:

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company’s common stock as quoted on the NYSE American as of ~~June~~September 30, 2021 for options that have a quoted market price in excess of the exercise price. There were 0 stock option awards exercised during the three and ~~six~~nine months ended ~~June~~September 30, ~~2021~~2021. ~~and~~ ~~2020.~~The Company received 0 cash payments for the exercise of stock options during the three and ~~six~~nine months ended ~~June~~September 30, ~~2021~~2021. There were 20 thousand stock option awards exercised during the threeand ~~2020.~~nine months ended September 30, 2020, for which the Company received cash payments of $6 thousand.

As of ~~June~~September 30, 2021, total unrecognized compensation cost related to unvested stock options and restricted stock units was approximately ~~$1.3~~$1.2 million. This amount is expected to be recognized as stock-based compensation expense in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss over the remaining weighted average vesting period of ~~2.47~~2.45 years.

The Company grants options to purchase common stock to its employees and directors at prices equal to or greater than the market value of the stock on the dates the options are granted. The Company has estimated the value of stock option awards as of the date of grant by applying the Black-Scholes option pricing model using the single-option valuation approach. The application of this valuation model involves assumptions that are judgmental and subjective in nature. See Note 2, “Summary of Significant Account Policies,” for a description of the accounting policies that the Company applied to value its stock-based awards.

During the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, the Company granted options to employees and directors to purchase an aggregate of ~~92,000~~291,000 and ~~520,000~~1,156,000 shares of common stock, respectively.

The weighted-average assumptions used in determining the value of options are as follows:

Expected Price Volatility—This is a measure of the amount by which the stock price has fluctuated or is expected to fluctuate. The computation of expected volatility was based on the historical volatility of our own stock.

Expected Term—This is the period of time over which the options granted are expected to remain outstanding. The expected life assumption is based on the Company’s historical data.

Risk-Free Interest Rate—This is the U.S. Treasury rate for the week of the grant having a term approximating the expected life of the option.

Dividend Yield—We have not made any dividend payments nor do we have plans to pay dividends in the foreseeable future.

Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous ~~estimate~~estimate.

In addition, during the ~~six~~nine months ended ~~June~~September 30, 2021, the Company granted ~~900,000~~1,228,359 shares of restricted stock to employees and directors. During the ~~six~~nine months ended ~~June~~September 30, 2020, the Company granted 160,000 shares of restricted stock to employees and directors.

For the three months ended ~~June~~September 30, 2021 and 2020, the Company recognized stock-based compensation expense of ~~$242~~$151 thousand and ~~$128~~$159 thousand, respectively, for stock-based awards to employees and directors. For the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, the Company recognized stock-based compensation expense of ~~$372~~$523 thousand and ~~$174~~$332 thousand, respectively, for stock-based awards to employees and directors.

In April 2020, the Company modified stock options held by Ms. Gail Maderis, who resigned as a director of the Company, effective April 1, 2020. The option exercise period for Ms. Maderis was extended from three months to three years, calculated from her date of resignation. Also, her stock option awards became fully vested at the date of her resignation. In connection with the stock option modification, the Company recognized incremental stock-based compensation expense of $36 thousand, which is included in the figure above.

In August 2020, the Company modified stock options held by Mr. Xiaopei Wang, who resigned as a director of the Company, effective August 21, 2020. The option exercise period for Mr. Wang was extended from three months to three years, calculated from his date of resignation. Also, his stock option awards became fully vested at the date of his resignation. In connection with the stock option modification, the Company recognized stock-based compensation expense of $17 thousand, which is included in the figure above.

During the ~~six~~nine months ended ~~June~~September 30, 2021, ~~and~~ ~~2020,~~the Company did not grant options exercisable for shares of common stock to non-employees in exchange for advisory and consulting services. During the nine months ended September 30, 2020, the Company granted 100,000 options exercisable for shares of common stock to non-employees in exchange for advisory and consulting services.

~~When the Company grants stock options, the~~The stock options are recorded at their fair value on the grant date and recognized over the respective service or vesting period. The fair value of the stock options that are granted is calculated using the Black-Scholes-Merton option pricing model ~~as discussed above.~~based upon the following assumptions:

~~In addition, during the~~ ~~six~~ ~~months ended~~ ~~June 30, 2021~~ ~~and~~ ~~2020,~~ ~~the Company did~~ ~~not~~ ~~grant restricted stock to non-employees.~~

For the three months ended ~~June~~September 30, 2021 and 2020, the Company recognized stock-based compensation expense of ~~$54~~$73 thousand and ~~negative $2~~$17 thousand, respectively, related to non-employee consultant stock and option grants. For the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, the Company recognized stock-based compensation expense of ~~$107~~$180 thousand and $9$27 thousand, respectively, related to non-employee consultant stock and option grants.

In connection with Mr. Mark Sieczkarek’s resignation in 2019, the Company also entered into a two-year consulting agreement with Mr. Sieczkarek (the “Consulting Agreement), pursuant to which Mr. Sieczkarek provided consulting service to the Company in exchange for restricted stock units from the Company’s 2017 Omnibus Incentive Plan with an aggregate fair market value equal to $440 thousand as of the date of grant. The restricted stock units were issued in two equal tranches on July 1, 2020 and July 1, 2021, respectively, with the share amount calculated using the closing price on each respective grant date. The shares were fully vested as of the date of grant. The expense related to this separation agreement was recorded over the term of the Consulting Agreement. In July 2020, the Company issued Mr. Sieczkarek 192,983 fully vested shares of registered stock pursuant to the Consulting Agreement. In July 2021, the Company issued Mr. Sieczkarek 328,359 fully vested shares of registered stock pursuant to the Consulting Agreement.

A summary of the stock-based compensation expense included in results of operations for the options and restricted stock awards discussed above is as follows (in thousands):

Transactions under the Company’s major distribution agreements are recognized upon transfer of control of product sold to its major distribution partners at the amount of consideration that the Company expects to be entitled to. The Company records contract liabilities for the amounts that are estimated to be subject to significant reversal, including allowances for services, discounts, rebate programs, and product returns.

The following table presents changes in the Company's contract assets and liabilities for the ~~six~~nine months ended ~~June~~September 30, 2021 (in thousands):

During the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, the Company recognized the following revenue (in thousands):

Prescription Avenova is made available in local pharmacies and major pharmacy retail chains under nationwide distribution agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen. We have also entered into direct agreements with preferred pharmacy networks as part of our Partner Pharmacy Program. During the three months ended ~~June~~September 30, 2021 and 2020, the Company earned $0.3 million and ~~$0.4~~$0.6 million, respectively, in sales revenue for its Avenova product from these distribution and partner pharmacy agreements. During the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, the Company earned ~~$0.4~~$0.6 million and ~~$0.9~~$1.6 million, respectively, in sales revenue for its Avenova product from these distribution and partner pharmacy agreements.

Under the prescription Avenova product distribution arrangements, the Company had a contract liability balance of ~~$0.9~~$0.6 million and $0.7 million at ~~June~~September 30, 2021 and December 31, 2020, respectively. The contract liability is included in accrued liabilities in the consolidated balance sheets. The Company also recorded a prepayment of ~~$42~~$40 thousand and $0.1 million for rebates related to these distribution agreements as of ~~June~~September 30, 2021 and December 31, 2020, respectively, that is recorded in the prepaid expenses and other current assets in the consolidated balance sheets. See Note 4, “Prepaid Expenses and Other Current Assets”.

Non-prescription Avenova was launched online on ~~June~~September 1, 2019 direct to U.S. customers. Over-the-counter Avenova is offered primarily for sale on Amazon.com, the Company’s website (Avenova.com) and Walmart.com as well as in CVS stores. Over-the-counter Avenova is the same strength hypochlorous formulation as our prescription Avenova product, but comes in a smaller size. This channel provides the Company with more stable pricing and provides customers with easy access to our product. During the three and ~~six~~nine months ended ~~June~~September 30, 2021, the revenue generated from over-the-counter Avenova was ~~$1.3~~$1.2 million and ~~$2.6~~$3.8 million, respectively. During the three and ~~six~~nine months ended ~~June~~September 30, 2020, the revenue generated from over-the-counter Avenova was ~~$0.6~~$1.0 million and ~~$1.4~~$2.4 million, respectively.

The Company has a 401(k) plan covering all eligible employees. The Company iswas not required to contribute to the plan and made 0 contributions during either the three or ~~six~~nine months ended ~~June~~September 30, 2021 or 2020. Due to a change in the terms of the 401(k) plan, beginning on January 1, 2022, the Company will be required to make a matching contribution equal to 100% of deferrals up to 3% of eligible pay plus 50% of deferrals between 3% and 5% of eligible pay.

The following table summarizes information about the Company’s related party revenue and cost of goods sold during the three and ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, respectively (in thousands):

Related party accounts receivable was $0.1 million and $0.2 million as of ~~June~~September 30, 2021 and December 31, 2020, respectively.

During the ~~six~~nine months ended ~~June~~September 30, 2021 and the year ended December 31, 2020, the Company purchased KN95 Masks through an affiliate of China Pioneer. As of ~~June~~September 30, 2021 and December 31, 2020, related party accounts payable was ~~$10 thousand~~$0 and $8 thousand, respectively.

The following table summarizes information about the Company’s other related party expenses excluding stock-based compensation during the three and ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, respectively (in thousands):

In connection with the Company's re-launch of CelleRx Clinical Reset, on November 17, 2020, the Company entered into a consulting agreement with Eric Wu (the “Consulting Agreement”). Eric Wu is Partner and Senior Vice President of China Kington and the brother of Bob Wu, who serves on the Company’s Board of Directors. Pursuant to the Consulting Agreement, Eric Wu will act as a consultant to the Company in support of the CelleRx product re-launch as well as in potential financings and other transaction opportunities. The term of the Consulting Agreement is for twelve months. As consideration for his services, the Company granted Eric Wu options exercisable for 300,000 shares of the Company’s common stock under the Company’s 2017 Omnibus Incentive Plan with an exercise price equal to the Company’s closing stock price on the date of the grant and vesting on the one-year anniversary of the grant date. There was 0 stock-based compensation expense recorded for the three or ~~six~~nine months ended ~~June~~September 30, 2020 related to Eric Wu’s options. For the three and ~~six~~nine months ended ~~June~~September 30, 2021, a fee of ~~$30~~$31 thousand and ~~$60~~$91 thousand, respectively, was recorded.

On May 6, 2020, the Company received loan proceeds in the amount of $0.9 million from Wells Fargo Bank, N.A. (the “PPP Loan”) pursuant to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), which was enacted on March 27, 2020.The terms of the PPP Loan were subsequently revised in accordance with the provisions of the Paycheck Protection Flexibility Act of 2020, or the PPP Flexibility Act, which was enacted on ~~June~~September 5, 2020. The PPP loan ~~provides~~provided for an interest rate of 1.00% per year and ~~matures~~maturity two years after the date of initial disbursement, with initial principal and interest payments coming due late in fiscal 2021. The Note could be prepaid by the Company at any time prior to the maturity with no prepayment penalties. Funds from the PPP Loan ~~may~~ could only be used for payroll costs, costs used to continue group health care benefits, rent and utilities incurred during the 24-week period after receiving the PPP Loan (collectively, “Qualifying Expenses”) in order for the PPP Loan to be forgiven in whole or in part. The Company used the entire PPP Loan amount for Qualifying Expenses.

Since the Company determined that there was reasonable assurance that it would meet the conditions for forgiveness of the full loan amount, the Company accounted for the forgivable PPP Loan as a government income grant that we earned through the Company’s compliance with the loan forgiveness criteria. A deferred income liability was recognized upon receipt of the forgivable loan proceeds. The deferred income liability was recognized as other income as Qualifying Expenses were incurred. For the three and ~~six~~nine months ended ~~June~~September 30, 2020, $~~469~~432 thousand and $901 thousand, respectively, was recognized as other income and recorded in the condensed consolidated statements of operations and comprehensive loss. No amount was recognized for the three ~~and~~or ~~six six~~nine months ended ~~June~~September 30, 2021.

The Company received notice, dated May 24, 2021, from Wells Fargo Bank, N.A. confirming the full loan amount of $0.9 million was forgiven.

On September 27, 2021, the Company entered into a Membership Unit Purchase Agreement by and among (i) the Company, (ii) DERMAdoctor, LLC, a Missouri limited liability company (“DERMAdoctor”), (iii) Jeff Kunin and Audrey Kunin, individuals residing in the State of Kansas; (iv) Papillon Partners, Inc., a Missouri corporation that is owned by the Founders; and (v) Midwest Growth Partners, L.L.L.P., an Iowa limited liability limited partnership. Pursuant to the Purchase Agreement, the Company will acquire 100% of the membership units of DERMAdoctor (the “Transaction”). DERMAdoctor is an omni-channel skincare company that was formed in 1998 and is primarily focused on the creation of products that are designed to target common skin concerns, ranging from aging and blemishes to dry skin, perspiration and keratosis pilaris. DERMAdoctor currently sells over 30 products under lines that include Ain’t Misbehavin’, Calm Cool + Corrected, Kakadu C, KP Duty, and Wrinkle Revenge and sells its products through major retailers such as Macy’s, QVC, Costco, digital beauty retailers such as SkinStore and Amazon, and its own website.

The Closing was subject to certain conditions, including the Company completing a financing to raise capital sufficient to fund the purchase price for the Transaction, which the Company completed in the fourth quarter of 2021 as described further in Note 19, “Subsequent Events”.

On ~~August 10,~~October 29, 2021, the Company ~~terminated~~entered into a Securities Purchase Agreement with certain purchasers named therein (the “Purchasers”). Pursuant to such Securities Purchase Agreement, the ~~Microprofit Agreement, dated~~Company agreed to sell in a private placement an aggregate of 15,000 shares of the Company’s Series B non-voting convertible preferred stock, par value $0.01 per share (the “Preferred Stock”) convertible into an aggregate of 37,500,000 shares (the “Conversion Shares”) of the Company’s common stock and common stock warrants (“Warrants”) exercisable for 37,500,000 shares (the “Warrant Shares”) of common stock for an aggregate purchase price of $15,000,000 (collectively, the “Private Placement”). The Company closed the Private Placement on ~~April 16, 2020,~~November 2, 2021. In connection with ~~Microprofit~~the Private Placement, the Company is seeking stockholder approval of the conversion of all of the Preferred Stock into the Conversion Shares and the ~~Distribution Agreement, dated~~ ~~April 16, 2020,~~ ~~with Chongqing Pioneer, as amended by~~exercisability of all of the ~~First Amendment, dated~~ ~~June 29, 2020,~~ ~~as further described in Note~~ 8, ~~“Commitments and Contingencies”.~~Warrants into the Warrant Shares.

~~Pursuant to the Microprofit Agreement and the Distribution Agreement, Microprofit granted the Company exclusive rights to distribute the Test Kits in the United States through~~On ~~December 31, 2021,~~ subject to various assumptions including the approval by the FDA, with Chongqing Pioneer to act as an intermediary between Microprofit and the Company in the distribution of the Test Kits if approved by the FDA. As previously disclosed, on ~~June 7,~~November 5, 2021, the Company ~~was notified by~~completed the ~~FDA that it declined to review~~acquisition of DERMAdoctor in accordance with the ~~Company’s Emergency Use Authorization request for~~terms of the ~~Test Kits. As such,~~Membership Unit Purchase Agreement. Following the ~~Test Kits are~~acquisition of DERMAdoctor, DERMAdoctor is now a wholly-owned subsidiary of the Company (see Note ~~not~~18, authorized to be distributed or used as proposed in the United States, and the Microprofit Agreement and Distribution Agreement were terminated by the parties mutual agreement for administrative and accounting purposes.“DERMAdoctor LLC Transaction”).

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read together with our consolidated financial statements and related notes included in Part I, Item 1 of this report, and with our consolidated financial statements and related notes, and Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission (the “SEC”) on March 25, 2021. This discussion contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “will,” “may,” “could,” “should,” “goals,” “potential,” “plans,” “believes,” “estimates,” “predicts,” “projects,” variations of these words, and similar expressions are intended to identify these forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions, estimates and facts as of the date hereof and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to:

As a result of many factors, such as those listed above and set forth under the section entitled “Risk Factors” in Part II, Item 1A elsewhere in this report or otherwise described in our filings with the SEC, you should not place undue reliance on these forward-looking statements. You should read this report and the documents that we reference and have filed as exhibits thoroughly and with the understanding that forward-looking statements represent our management’s beliefs and assumptions only as of the date of this report and our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

We are a medical device company predominantly focused on eye care. A majority of our revenue comes from Avenova®, an FDA cleared product sold in the United States that has proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from skin around the eye, including the eyelid. Avenova is formulated with our proprietary, stable and pure form of hypochlorous acid. Avenova is available directly to consumers through our online sales channel and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.

We continue to promote Avenova through all four of our primary distribution channels: (1) our over-the-counter direct-to-consumer model, allowing customers to purchase either online or at select brick and mortar stores; (2) retail pharmacies, dispensing Avenova to patients through national pharmacy chains across all 50 states; (3) our Partner Pharmacy Program, providing a consistent patient experience at contracted pricing; and (4) our physician dispensed channel, allowing patients to buy Avenova during office visits to their preferred eye care ~~specialist We continue to achieve record overall Avenova unit sales quarter over quarter with more people using Avenova than ever before.~~specialist.

Avenova was launched as a prescription only product in 2016. To expand our addressable market, we launched Avenova as an over-the-counter product during the second quarter of 2019. By creating a consumer driven product that does not require a doctor’s prescription, we made Avenova available to many more potential customers. Over-the-counter Avenova also capitalizes on a trend to sell over-the-counter pharmaceutical products directly to consumers and adds convenience by allowing customers to forego a time-consuming doctor visit and trip to the pharmacy.

Over-the-counter Avenova is now our leading product by unit sales and net revenue despite having a lower average net selling price than ~~prescription Avenova.~~Avenova sold through pharmacy channels. This sales performance reflects our ongoing focus and ~~increasing~~ spend on digital marketing, social media and public relations initiatives to promote Avenova directly to the end consumer. Avenova is available on Amazon.com, Walmart.com, and Avenova.com. Beginning in February 2021, Avenova became available at CVS store locations throughout the U.S. and on CVS.com, one of the nation’s largest retail chains.

Last year, we responded to the national need for PPE by tapping into our international supply network and launching the sale of KN95 Masks and other PPE. Although sales from the KN95 Masks were significant in the second quarter of 2020, we experienced a significant decrease in PPE sales ~~in the third and fourth quarters of 2020~~ as supply shortages narrowed, prices declined and distribution competition increased. We have returned our focus to our core business in eyecare and we do not anticipate dedicating future Company resources toward the sale of PPE and we do not expect future revenue from PPE sales.

During the second quarter of this year, we introduced two complementary products to support the use of Avenova. Our Warm Eye Compress not only provides effective heat therapy for many eye conditions, but it also improves Avenova’s ability to restore the eyes’ natural defenses against tear evaporation. Additionally, the i-Chek Illuminated Eye Examination Mirror allows Avenova customers to get a closer look at common eye conditions that are often of concern to Avenova customers. These eye conditions include blepharitis, chalazion and styes. The i-Chek also helps Avenova users who suffer from dry eye to identify dirt, oil or debris that need to be removed from the eyelids and eyelashes for optimum ocular health. The use of Avenova and both products is meant to provide Avenova customers with a holistic approach to lid and lash hygiene.

Our condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these condensed consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. In preparing these condensed consolidated financial statements, management has made its best estimates and judgments of certain amounts, giving due consideration to materiality. On an ongoing basis, we evaluate our estimates and judgments related to revenue recognition, research and development costs, patent costs, stock-based compensation, income taxes and other contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances. Actual results may differ from these estimates.

While our significant accounting policies are more fully described in Note 2, “Summary of Significant Accounting Policies” to the Notes to Unaudited Condensed Consolidated Financial Statements, included in Part I, Item 1 of this report, we believe that the following accounting policies are most critical to fully understanding and evaluating our reported financial results.

The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identifies amounts due that are in dispute and it believes are unlikely to be collected. Management recorded no reserve for accounts receivable at ~~June~~September 30, 2021 and December 31, 2020.

Inventory is comprised of (1) raw materials and supplies, such as bottles, packaging materials, labels, boxes and pumps; (2) goods in progress, which are normally filled but unlabeled bottles; and (3) finished goods. We utilize contract manufacturers to produce our products and the price paid to these manufacturers is included in inventory. Inventory is stated at the lower of cost or estimated net realizable value determined by the first-in, first-out method. At both ~~June~~September 30, 2021 and December 31, 2020, management ~~had~~ recorded an allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments of $0.1 million and $0.2 ~~million.~~million, respectively.

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid or incentives received.

Revenue generated through the Company’s webstores, Avenova.com and CelleRx.com, for Avenova and CelleRx (as well as the KN95 Masks previously offered and sold) is recognized upon receipt by the customer through multiple third-party carriers. Shipping and handling costs are expensed as fulfillment costs and are incurred and included in cost of goods sold in the consolidated statements of operations and comprehensive loss. We present revenue net of sales taxes and refunds.

Revenue generated through Amazon.com and Walmart.com for Avenova and other products is recognized upon fulfillment, which generally occurs upon delivery of the related products to a third-party carrier or, in the case of an Amazon or Walmart delivery, to the customer. We present revenue net of commissions and any related fulfillment and shipping fees charged by these partners. Fees paid to partners for promoting our product are expensed as incurred and are included in sales and marketing expenses within the operating expenses in the consolidated statements of operations and comprehensive loss.

The Company also generates Avenova product revenue through product sales to its major distribution partners. Product supply of Avenova is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon shipment to the distributor on a “sell-in” basis. Upon recognition of product sales, contract liabilities are recorded for invoiced amounts that are subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, and product returns. The Company derives its rate of return from historical data and updates its return rate assumption quarterly. Payment for product supply is typically due 30 days after control transfers to the distributor.

Revenue generated through the Company’s partner pharmacies is recognized when control of the product transfers to the end customer.

Revenue for product sales to CVS is recognized upon transfer of control to CVS, which generally occurs upon delivery of the related products to a third-party carrier, net of estimated future product returns.

The following table summarizes the activity in the accounts related to product revenue allowances during the ~~six~~nine months ended ~~June~~September 30, 2021 (in thousands):

Cost of goods sold includes third-party manufacturing costs, shipping and handling costs, and other costs associated with products sold. Cost of goods sold also includes any necessary allowance for excess and obsolete inventory along with lower of cost and estimated net realizable value.

The Company’s stock-based compensation includes grants of stock options and restricted stock units (“RSUs”) to employees, non-employee directors and consultants. The expense associated with these grants is recognized in the Company’s consolidated statements of operations and comprehensive loss based on their fair values as they are earned under the applicable vesting terms. For stock options granted, the fair value of the stock options is estimated using a Black-Scholes option pricing model. See Note 13, “Equity-Based Compensation” for further information regarding stock-based compensation expense and the assumptions used in estimating that expense. The Company accounts for RSUs issued to employees and non-employees (board members and consultants) based on the fair market value of the Company’s common stock as of the date of issuance.

The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized.

The Company accounts for common stock purchase warrants issued in connection with its equity offerings in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging.

The Company accounts for common stock purchase warrants issued in connection with share-based compensation arrangements in accordance with the provisions of ASC 718, Stock Compensation, which encompasses the provisions of ASC 480, Distinguishing Liabilities from Equity.

The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). Additionally, for common stock purchase warrants accounted for in accordance with ASC 718, Stock Compensation, the Company classifies as liabilities any contracts where it believes the warrants are deemed to be probable of issuance.

See Note 2, “Summary of Significant Accounting Policies” to the Notes to Unaudited Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for information on recent accounting pronouncements.

Comparison of the Three Months Ended ~~June~~September 30, 2021 and 2020

Product revenue, net, decreased by ~~$1.9~~$0.3 million, or ~~47%~~15%, to ~~$2.1~~$1.8 million for the three months ended ~~June~~September 30, 2021, from ~~$4.0~~$2.2 million for the three months ended ~~June~~September 30, 2020. The change in product revenue, net, is primarily the result of $0.2 million in revenue, net, generated from sales of PhaseOne, a private label prescription skin and wound care product, and $0.1 million in revenue, net, generated from the sale of ~~KN95 Masks resulting in $2.8 million in product revenue, net,~~PPE, during the three months ended ~~June~~September 30, 2020 with no comparable revenue in the 2021 period. We do not anticipate dedicating future Company resources toward the sale of KN95 Masks or other PPE and we do not expect any 2021 or future revenue from KN95 Masks or other PPE.

Avenova revenue, ~~increased by 65% to $1.9~~net, was $1.8 million for both the three months ended ~~June~~September 30, 2021 ~~from $1.1 million for the three months ended June 30,~~and 2020. The increase reflects a continued higher number of overall Avenova units sold, primarily a result of an increase in the number of over-the-counter units. The increase in over-the-counter units includes the impact of our ongoing focus and increasing spend on digital marketing initiatives to promote Avenova directly to end consumers. The increase was partially offset by a decrease in the number of units sold through our pharmacy channels. The overall increase in revenue due to unit sales was also partially offset by the lower average net selling price associated with over-the-counter units as compared to units sold through our pharmacy channels.

Cost of goods sold decreased by ~~$1.4 million,~~$43 thousand or ~~70%~~8%, to ~~$0.6 million~~$493 thousand for the three months ended ~~June~~September 30, 2021, from ~~$2.0 million~~$536 thousand for the three months ended ~~June~~September 30, 2020. The decrease was primarily the result of cost of goods sold from the sale of ~~KN95 Masks~~PhaseOne and PPE during the three months ended ~~June~~September 30, 2020, with no comparable result in the 2021 period. This decrease was partially offset by the overall increase in the number of Avenova units sold during the three months ended ~~June~~September 30, 2021, as compared to the 2020 period.

Gross profit decreased by ~~$0.4~~$0.3 million, to ~~$1.5~~$1.3 million for the three months ended ~~June~~September 30, 2021, from ~~$1.9~~$1.6 million for the three months ended ~~June~~September 30, 2020. The decrease was primarily ~~the result of~~due to the lack of sales of the KN95 Masks and other PPE in the 2021 period, partially offset by the increase in overall Avenova revenue.

Research and development expenses decreased by ~~$94~~$115 thousand to ~~$21~~$10 thousand for the three months ended ~~June~~September 30, 2021, from ~~$115~~$125 thousand for the three months ended ~~June~~September 30, 2020. The decrease was primarily the result of one-time regulatory expenses incurred in the 2020 period under the Microprofit Agreement as further described in Note 8, “Commitments and Contingencies”, of the Notes to Unaudited Condensed Consolidated Financial Statements, included in Part I, Item 1 of this report, with no comparable expenditures in the 2021 period. ~~The parties mutually agreed to terminate the agreement on August 10, 2021.~~

Sales and marketing expenses increased by ~~$0.4~~$0.2 million, or ~~26%~~10%, to ~~$1.8~~$1.9 million for the three months ended ~~June~~September 30, 2021, from ~~$1.4~~$1.7 million for the three months ended ~~June~~September 30, 2020. The increase was primarily due to an increase in Avenova ~~and CelleRx~~ digital advertising and related consulting costs and was partly off-set by a decrease in sales representative headcount.

General and administrative expenses ~~increased~~decreased by $0.1 million, to ~~$1.6~~$1.8 million for the three months ended ~~June~~September 30, 2021, from ~~$1.5~~$1.9 million for the three months ended ~~June~~September 30, 2020. The ~~increase~~decrease was primarily the result of ~~an increase in~~legal expenses and the ~~overall cost of general and administrative personnel which was partially offset by a decrease in the cost of consultants and legal expenses. The 2020 period includes legal expenses~~settlement amount incurred in conjunction with a dispute with the Company’s former Interim President & Chief Executive Officer and Chief Financial Officer (see Note 8, “Commitments and Contingencies”) in the 2020 period with no comparable costs incurred in the 2021 period. This decrease was partially offset by legal costs incurred in the 2021 period in conjunction with the Company’s acquisition of DERMAdoctor (see Item 1, Note 18, “DERMAdoctor LLC Transaction”) with no comparable cost incurred in the 2020 period. The Company expects general and administrative expenses to increase temporarily due to continued costs to close the acquisition and costs to integrate DERMAdoctor’s operations, primarily in the fourth quarter of 2021 and the first quarter of 2022.

The Company recorded a non-cash loss on a change in fair value of warrant liability of ~~$3.8~~$1.6 million for the three months ended ~~June~~September 30, 2020. There was no comparable result for the three months ended ~~June~~September 30, 2021. For additional information regarding the warrants and their valuation, please see Note 11, “Warrant Liability”, to the Notes to Unaudited Condensed Consolidated Financial Statements, included in Part I, Item 1 of this report.

The adjustment to the fair value of embedded derivative liability resulted in a gain of $1 thousand for the three months ended September 30, 2020. There was no comparable adjustment for the nine months ended September 30, 2021. For additional information, please see Note 10, “Convertible Note”, of the Notes to Unaudited Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.

The Company recorded other income, net of ~~$362~~$429 thousand for the three months ended ~~June~~September 30, 2020. There was no comparable result for the three months ended ~~June~~September 30, 2021. The 2020 result consisted primarily of income of ~~$469~~$432 thousand representing qualifying expenses incurred under the PPP loan program. For additional information, see Note 17 “Paycheck Protection Program” The income was partially offset by the interest due on the Promissory Note issued in February 2019 and the amortization of discount and issuance cost related to the Convertible Note issued in March 2019. For additional information regarding the Promissory Note and Convertible Note, please see Note 9, “Related Party Note Payable” and Note 10, “Convertible Note”, to the Notes to Unaudited Condensed Consolidated Financial Statements in Part 1, Item 1 of this report.”

Comparison of the ~~Six~~Nine Months Ended ~~June~~September 30, 2021 and 2020

Product revenue, net, decreased by ~~$1.9~~$2.3 million, or ~~33%~~28%, to ~~$3.9~~$5.8 million for the ~~six~~nine months ended ~~June~~September 30, 2021, from ~~$5.9~~$8.0 million for the ~~six~~nine months ended ~~June~~September 30, 2020. The change in product revenue, net, is primarily the result of revenue generated from the sale of KN95 Masks and other PPE resulting in ~~$3.0~~$3.1 million in product revenue, net, during the ~~six~~nine months ended ~~June~~September 30, 2020 with no comparable revenue in the 2021 period. We do not anticipate dedicating future Company resources toward the sale of KN95 Masks or other PPE and we do not expect any 2021 or future revenue from KN95 Masks or other PPE.

Avenova revenue increased by ~~29%~~16% to ~~$3.5~~$5.2 million for the ~~six~~nine months ended ~~June~~September 30, 2021, from ~~$2.7~~$4.5 million for the ~~six~~nine months ended ~~June~~September 30, 2020. The increase reflects a continued higher number of overall Avenova units sold, primarily a result of an increase in the number of over-the-counter units. The increase in over-the-counter units includes the impact of our ongoing focus and increasing spend on digital marketing and social media initiatives to promote Avenova directly to end consumers. ~~The increase was partially offset by a decrease in the number of units sold through our pharmacy channels.~~ The overall increase in revenue due to unit sales was also partially offset by the lower average net selling price associated with over-the-counter units as compared to units sold through our pharmacy channels.

Cost of goods sold decreased by $1.6 million, or ~~59%~~51%, to ~~$1.1~~$1.6 million for the ~~six~~nine months ended ~~June~~September 30, 2021, from ~~$2.6~~$3.2 million for the ~~six~~nine months ended ~~June~~September 30, 2020. The decrease was primarily the result of cost of goods sold from the sale of KN95 Masks and other PPE during the ~~six~~nine months ended ~~June~~September 30, 2020, with no comparable result in the 2021 period. This decrease was partially offset by the overall increase in the number of Avenova units sold during the ~~six~~nine months ended ~~June~~September 30, 2021, as compared to the 2020 period.

Gross profit decreased by ~~$0.4~~$0.7 million, to ~~$2.9~~$4.2 million for the ~~six~~nine months ended ~~June~~September 30, 2021, from ~~$3.3~~$4.9 million for the ~~six~~nine months ended ~~June~~September 30, 2020. The decrease was primarily due to the ~~result~~lack of sales of the ~~Company no longer selling the~~ KN95 Masks and other PPE in the 2021 period, partially offset by the increase in overall Avenova revenue.

Research and development expenses decreased by ~~$98~~$213 thousand to ~~$26~~$36 thousand for the ~~six~~nine months ended ~~June~~September 30, 2021, from ~~$124~~$249 thousand for the ~~six~~nine months ended ~~June~~September 30, 2020. The decrease was primarily the result of one-time regulatory expenses incurred in the 2020 period under the Microprofit Agreement as further described in Note 8, “Commitments and Contingencies”, of the Notes to Unaudited Condensed Consolidated Financial Statements, included in Part I, Item 1 of this report, with no comparable expenditures in the 2021 period. ~~The parties mutually agreed to terminate the agreement on August 10, 2021.~~

Sales and marketing expenses increased by ~~$0.5~~$0.6 million, or ~~16%~~14%, to ~~$3.5~~$5.3 million for the ~~six~~nine months ended ~~June~~September 30, 2021, from ~~$3.0~~$4.7 million for the ~~six~~nine months ended ~~June~~September 30, 2020. The increase was primarily due to an increase in Avenova and CelleRx digital advertising and related consulting costs and was partly off-set by a decrease in sales representative headcount.

General and administrative expenses remained consistent for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020.

The ~~adjustments~~adjustment to the fair value of warrant liability resulted in a loss of ~~$3.6~~$5.2 million for the ~~six~~nine months ended ~~June~~September 30, 2020. There was no comparable ~~result~~adjustment for the ~~six~~nine months ended ~~June~~September 30, 2021. For additional information regarding the warrants and their valuation, please see Note 11, “Warrant Liability”, in the Notes to Unaudited Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.

The ~~adjustments~~adjustment to the fair value of embedded derivative liability resulted in a gain of $2$3 thousand for the ~~six~~nine months ended ~~June~~September 30, 2020. There was no comparable ~~result~~adjustment for the ~~six~~nine months ended ~~June~~September 30, 2021. For additional information, please see Note 10, “Convertible Note”, of the Notes to Unaudited Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.

The other income, net, was $2 thousand and ~~$176~~$605 thousand for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, respectively. For the ~~six~~nine months ended ~~June~~September 30, 2020, we recognized income of ~~$469~~$901 thousand which was a result of income recognized as a qualifying expense ~~which were~~ incurred under the PPP Loan. For additional information, see Note 17, “Paycheck Protection Program”. This income was partially offset by the interest due on the Promissory Note issued in February 2019 and the amortization of discount and issuance cost related to the Convertible Note issued in March 2019. For additional information regarding the Promissory Note and Convertible Note, please see Note 9, “Related Party Note Payable” and Note 10, “Convertible Note”, to the Notes to Unaudited Condensed Consolidated Financial Statements in Part 1, Item 1 of this report.”

As of ~~June~~September 30, 2021, our cash and cash equivalents were ~~$10.3~~$9.0 million, compared to $12.0 million as of December 31, 2020. Based ~~primarily~~ on ~~the~~our funds available ~~at June~~on September 30, 2021, and proceeds from the Company’s private placement of its Series B Non-Voting Convertible Preferred Stock and common stock warrants that was completed on November 2, 2021, management believes that the Company’s existing cash and cash equivalents and cash flows generated from product sales will be sufficient to enable the Company to meet its planned operating expenses at least through ~~August~~November 12, ~~2022.~~2022, including the cost to acquire and integrate DERMAdoctor (see Item 1, Note 18, “DERMAdoctor LLC Acquisition”). However, changing circumstances may cause the Company to expend cash significantly faster than currently anticipated, and the Company may need to spend more cash than currently expected because of circumstances beyond its control. Additionally, our future results, cash expenditures and ability to obtain additional external financing could be adversely affected by the COVID-19 pandemic and general adverse economic conditions. The Company also may consider other plans to fund operations including raising additional capital through debt and equity financings or from other sources. The Company may issue securities, including common stock and warrants, through private placement transactions or registered public offerings (including the ATM Program), which may require the filing of a Form S-1 or Form S-3 registration statement with the Securities and Exchange Commission (the “SEC”). Notably, the Company has completed the Private Placement for gross proceeds of $15.0 million, and the terms of such Private Placement include certain restrictions regarding the Company’s right to raise further capital, including the Company being restricted from (i) issuing or entering into any agreement to issue any shares of common stock or common stock equivalents, (ii) incurring, entering into any agreement to incur or announcing the incurrence or proposed incurrence of any indebtedness, or (iii) filing any registration statement or any amendment or supplement thereto, until ninety (90) days after certain stockholder approval has been received in connection with the Private Placement and certain registration statements for the securities issued in the Private Placement have been declared effective. Additionally, our future results, cash expenditures and ability to obtain additional external financing could be adversely affected by the COVID-19 pandemic and general adverse economic conditions.

Net cash used in operating activities was ~~$3.4~~$4.9 million for the ~~six~~nine months ended ~~June~~September 30, 2021, which consisted primarily of a net loss of ~~$3.4~~$5.7 million, adjusted by stock-based compensation expenses of ~~$0.5~~$0.7 million, and a net change of ~~$0.5 million~~$42 thousand in our net operating assets and liabilities.

Net cash used in operating activities was ~~$1.9~~$3.3 million for the ~~six~~nine months ended ~~June~~September 30, 2020, which consisted primarily of a net loss of ~~$6.1~~$9.3 million, ~~due to increased product sales combined with reduction~~adjusted by non-cash loss of $5.2 million on the change in ~~insurance coverage~~fair value of ~~the product by national payors, loss on change of the~~ warrant liability, ~~fair value by $3.6 million, decrease in~~ stock compensation expenses of ~~$0.1~~$0.4 million, ~~loss on change~~issuance of ~~the derivative liability fair value by $2 thousand and~~RSUs for services of $0.2 million, non-cash interest expense related to amortization of debt issuance cost and debt discount of $0.1 ~~million.~~million, and a net increase of $0.1 million in our net operating assets and liabilities.

For the ~~six~~nine months ended ~~June~~September 30, 2021, net cash used in investing activities for the purchase of property and equipment was ~~$27~~$44 thousand ~~with no comparable result~~and $5 thousand for the ~~six~~nine months ended ~~June~~September 30, ~~2020.~~2021 and 2020, respectively.

Net cash provided by financing activities was ~~$1.8~~$2.0 million for the ~~six~~nine months ended ~~June~~September 30, 2021. The Company received net proceeds of $1.8 million raised from the ATM program pursuant to the ATM Agreement, dated May 14, 2021, with Ladenburg.

Net cash provided by financing activities was ~~$3.7~~$9.8 million for the ~~six~~nine months ended ~~June~~September 30, 2020. The Company received net proceeds of $5.2 million from the ATM Program, and an additional ~~$0.7~~$7.1 million from exercise of warrants, which was offset by repayments of ~~$1.1~~$1.6 million on the Convertible Note issued to Iliad Research and Trading L.P. and repayment of $1.0 million on the Promissory Note using proceeds raised through the ATM program pursuant to the ATM Agreement, dated April 27, 2020, with Ladenburg.

We do not believe that inflation has had a material impact on our business and operating results during the periods presented, and we do not expect it to have a material impact in the near future, although there can be no assurances that our business will not be affected by inflation in the future.

Consistent with our peers in the United States pharmaceutical industry, our prescription business experiences seasonality with the first quarter of each year typically being the lowest revenue quarter. This annual phenomenon is due to consumers facing the need to satisfy health insurance deductibles and changes to copays as each new insurance year begins.

Our contractual cash commitments as of ~~June~~September 30, 2021 were as follows (in thousands):

Our commitments as of ~~June~~September 30, 2021 consisted primarily of a facility operating lease and an operating lease for two copiers.

The total commitment for the facility lease as of ~~June~~September 30, 2021 was ~~$0.3~~$0.2 million due over the lease term, compared to $0.5 million as of December 31, 2020.

We had an operating lease for 2 copiers as of ~~June~~September 30, 2021. The total commitment for the lease as of ~~June~~September 30, 2021 was ~~$22~~$17 thousand due over the lease terms, compared to $29 thousand as of December 31, 2020.

See Note 8, “Commitments and Contingencies” to the Notes to Unaudited Condensed Consolidated Financial Statements in Part I, Item 1 of this report for further information regarding these leases.

~~The disclosure set forth~~On October 29, 2021, the Company entered into a Securities Purchase Agreement with the Purchasers. Pursuant to such Securities Purchase Agreement, the Company agreed to sell in ~~Part II, Item 5~~a private placement an aggregate of ~~this report regarding the termination~~15,000 shares of the ~~Microprofit Agreement~~Preferred Stock convertible into an aggregate of 37,500,000 Conversion Shares and Warrants exercisable for 37,500,000 Warrant Shares for an aggregate purchase price of $15,000,000. The Company closed the Private Placement on November 2, 2021. In connection with the Private Placement, the Company is seeking stockholder approval of the conversion of all of the Preferred Stock into the Conversion Shares and the ~~Distribution Agreement~~exercisability of all of the Warrants into the Warrant Shares.

On November 5, 2021, the Company completed the acquisition of DERMAdoctor in accordance with the terms of the Membership Unit Purchase Agreement. Following the acquisition of DERMAdoctor, DERMAdoctor is ~~incorporated herein by reference.~~now a wholly-owned subsidiary of the Company.

Our market risk consists principally of interest rate risk on our cash and cash equivalents.

With most of our focus on Avenova in the domestic U.S. market, we do not have any material exposure to foreign currency rate fluctuations.

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 and 15d-15 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Assessing the costs and benefits of such controls and procedures necessarily involves the exercise of judgment by management. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

Based upon that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance level to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act was accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

There was no change in our internal control over financial reporting during the quarter ended ~~June~~September 30, 2021, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

The “Legal Matters” section of Note 8. “Commitments and Contingencies” to the Notes to Unaudited Condensed Consolidated Financial Statements in Part I, Item 1 of this report is incorporated herein by reference.

For information regarding factors that could affect our business, results of operations, financial condition and liquidity, see the risk factors discussed under Part I, Item 1A included in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on March 25, 2021, and the section titled “Risk Factors” in the Company’s Preliminary Proxy Statement, filed with the SEC on November 2, 2021. We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, are not required to provide updated quarterly information under this Item.

On August 10, 2021, the Company terminated the Microprofit Agreement, dated April 16, 2020, with Microprofit and the Distribution Agreement, dated April 16, 2020, with Chongqing Pioneer, as amended by the First Amendment, dated June 29, 2020, the terms of which were previously disclosed in the Company’s Current Report on Form 8-K filed with the SEC on April 20, 2020 and the Company’s Quarter Report on Form 10-Q filed with the SEC on August 6, 2020.

Pursuant to the Microprofit Agreement and the Distribution Agreement, Microprofit granted the Company exclusive rights to distribute the Test Kits in the United States through December 31, 2021, subject to various assumptions including the approval by the FDA, with Chongqing Pioneer to act as an intermediary between Microprofit and the Company in the distribution of the Test Kits if approved by the FDA. As previously disclosed, on June 7, 2021, the Company was notified by the FDA that it declined to review the Company’s Emergency Use Authorization request for the Test Kits. As such, the Test Kits are not authorized to be distributed or used as proposed in the United States, and the Microprofit Agreement and Distribution Agreement were terminated by the parties mutual agreement for administrative and accounting purposes.None.

The following exhibits are filed with or incorporated by reference into this report.

*Certain schedules and exhibits were omitted as well as certain confidential portions of the agreements by means of marking such portions with brackets (due to such confidential portions are not material and would be competitively harmful if publicly disclosed) pursuant to Item 601 of Regulation S-K promulgated by the SEC. The Company agrees to supplementally furnish a copy of any omitted schedule, exhibit or confidential portions to the SEC upon request.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended September 30,						Nine Months Ended September 30,
	2021			2020			2021			2020			2021			2020			2021			2020
Sales:
Product revenue, net	$	2,126		$	3,979		$	3,927		$	5,871		$	1,834		$	2,167		$	5,761		$	8,038
Other revenue, net		7			5			13			5			6			3			19			8
Total sales, net		2,133			3,984			3,940			5,876			1,840			2,170			5,780			8,046

Product cost of goods sold		614			2,040			1,069			2,621			493			536			1,562			3,157
Gross profit		1,519			1,944			2,871			3,255			1,347			1,634			4,218			4,889
Operating expenses:
Research and development		21			115			26			124			10			125			36			249
Sales and marketing		1,788			1,423			3,468			2,983			1,855			1,692			5,323			4,675
General and administrative		1,569			1,477			2,756			2,754			1,771			1,879			4,527			4,633
Total operating expenses		3,378			3,015			6,250			5,861			3,636			3,696			9,886			9,557
Operating loss		(1,859	)		(1,071	)		(3,379	)		(2,606	)		(2,289	)		(2,062	)		(5,668	)		(4,668	)

Non-cash loss on changes in fair value of warrant liability		0			(3,772	)		0			(3,635	)		0			(1,589	)		0			(5,224	)
Non-cash gain on changes in fair value of embedded derivative liability		0			0			0			2			0			1			0			3
Other income, net		0			362			2			176			0			429			2			605

Loss before provision for income taxes		(1,859	)		(4,481	)		(3,377	)		(6,063	)		(2,289	)		(3,221	)		(5,666	)		(9,284	)
Provision for income taxes		0			(1	)		0			(1	)		0			0			0			(1	)
Net loss and comprehensive loss	$	(1,859	)	$	(4,482	)	$	(3,377	)	$	(6,064	)	$	(2,289	)	$	(3,221	)	$	(5,666	)	$	(9,285	)

Net loss per share (basic and diluted)	$	(0.04	)	$	(0.15	)	$	(0.08	)		(0.21	)	$	(0.05	)	$	(0.08	)	$	(0.13	)	$	(0.28	)
Weighted-average shares of common stock used in computing net loss per share (basic and diluted)		42,561			30,384			42,174		$	29,012			44,921			40,037			43,100			32,614

	Six Months Ended June 30,				Nine months Ended September 30,
	2021		2020		2021		2020
Supplemental disclosure of cash flow information:
Interest paid	$	0	$	55	$	0	$	61

Supplemental disclosure of non-cash information:
Non-cash payment of related party loan accrued interest	$	0	$	173
offset by related party accounts receivable
Warrant liability transferred to equity					$	0	$	9,293
Non-cash payment of related party loan accrued interest offset by related party accounts receivable					$	0	$	173

	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended September 30,				Nine months Ended September 30,
	2021		2020		2021		2020		2021		2020		2021		2020
Avenova	$	1,883	$	1,140	$	3,458	$	2,686	$	1,763	$	1,835	$	5,221	$	4,509
KN95 Masks		0		2,839		0		3,012		0		69		0		3,081
NeutroPhase		175		0		175		173
Other products		68		0		294		0		71		263		540		448
Total product revenue, net		2,126		3,979		3,927		5,871		1,834		2,167		5,761		8,038
Other revenue, net		7		5		13		5		6		3		19		8
Total sales, net	$	2,133	$	3,984	$	3,940	$	5,876	$	1,840	$	2,170	$	5,780	$	8,046

	Three Months Ended June 30,						Six Months Ended June 30,
Numerator	*2021*			*2020*			*2021*			*2020*
Net loss	$	(1,859	)	$	(4,482	)	$	(3,377	)	$	(6,064	)

Denominator
Weighted average shares of common stock outstanding, basic and diluted		42,561			30,384			42,174			29,012
Net loss per share, basic and diluted	$	(0.04	)	$	(0.15	)	$	(0.08	)	$	(0.21	)

	As of June 30,				As of September 30,
	2021		2020		2021		2020
Stock options		3,873		2,692		3,947		3,328
Stock warrants		7,082		7,105		7,082		7,067
		10,955		9,797		11,029		10,395

	June 30,		December 31,		September 30,		December 31,
	2021		2020		2021		2020
Cash and cash equivalents	$	10,294	$	11,952	$	9,028	$	11,952
Restricted cash included in other assets		475		475		475		475
Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows	$	10,769	$	12,427	$	9,503	$	12,427

	June 30,			December 31,
Major distribution partner	2021			2020
Distributor C		29	%		14	%
Distributor A		19	%		18	%
CVS		14	%		*	%
Avenova Direct via Amazon		13	%		11	%
Congqing Pioneer Pharma Holdings Limited		10	%		16	%
Distributor B		*			14	%

			Fair Value Measurements Using								Fair Value Measurements Using
Assets	Balance at June 30, 2021		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Balance at September 30, 2021		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Restricted cash held as a certificate of deposit	$	324	$	324	$	0	$	0	$	324	$	324	$	0	$	0
Deposit held as a certificate of deposit		151		151		0		0		151		151		0		0
Total assets	$	475	$	475	$	0	$	0	$	475	$	475	$	0	$	0

			Fair Value Measurements Using
Assets	Balance at December 31, 2020		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Restricted cash held as a certificate of deposit	$	324	$	324	$	0	$	0
Deposit held as a certificate of deposit		151		151		0		0
Total assets	$	475	$	475	$	0	$	0

Lease Costs	Three Months Ended June 30,					Six Months Ended June 30,					Three Months Ended September 30,					Nine months Ended September 30,
	2021		2020			2021		2020			2021		2020			2021		2020
Operating lease cost	$	99	$	250		$	199	$	514		$	99	$	212		$	298	$	726
Sublease income		0		(158	)		0		(316	)		0		(105	)		0		(421	)
Net lease cost	$	99	$	92		$	199	$	198		$	99	$	107		$	298	$	305

Other information
Operational cash flow used for operating leases	$	113	$	284		$	226	$	580		$	113	$	236		$	339	$	816

2021	$	228		$	114
2022		89			88
Thereafter		0
Total future minimum lease payments		317			202
Less imputed interest		(14	)		(6	)
Total	$	303		$	196

Reported as:
Operating lease liability	$	298		$	195
Operating lease liability- non-current		5			1
Total	$	303		$	196

Assumptions	2019 Domestic Warrants			2019 Foreign Warrants
Expected price volatility		178	%		178	%
Expected term (in years)		4.57			4.57
Risk-free interest rate		0.25	%		0.27	%
Dividend yield		0.00	%		0.00	%
Weighted-average fair value of warrant	$	1.18		$	1.54

Expected price volatility		186	%
Expected term (in years)		4.05
Risk-free interest rate		0.22	%
Dividend yield		0.00	%
Weighted-average fair value of warrants	$	1.17

	Warrants (in thousands)		Weighted- Average Exercise Price		Warrants (in thousands)		Weighted- Average Exercise Price
Outstanding at December 31, 2020		7,067	$	1.63		7,067	$	1.63
Warrants granted		15	$	0.67		15	$	0.67
Warrants exercised		0	$	0		0	$	0
Warrants expired		0	$	0		0	$	0
Outstanding at June 30, 2021		7,082	$	1.63
Outstanding at September 30, 2021						7,082	$	1.63

(in thousands, except years and per share data)	Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (years)		Aggregate Intrinsic Value		Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (years)		Aggregate Intrinsic Value
Outstanding at December 31, 2020		3,165		$	2.05		7.6	$	189		3,165		$	2.05		7.6	$	189
Options granted		92		$	0.94						291		$	0.74
Sales and marketing		900		$	0
Restricted stock units granted											1,228		$	—
Options exercised		0		$	0						-		$	—
Restricted stock units vested		(160	)	$	0						(488	)	$	—
Options forfeited/cancelled		(124	)	$	3.19						(249	)	$	2.39
Restricted stock units cancelled		0		$	—						0		$	—
Outstanding at June 30, 2021		3,873		$	1.59		7.7	$	669
Outstanding at September 30, 2021											3,947		$	1.54		7.6	$	633

Vested and expected to vest at June 30, 2021		3,480		$	1.69		7.6	$	593
Vested and expected to vest at September 30, 2021											3,601		$	1.64		7.4	$	562

Vested at June 30, 2021		1,564		$	3.06		5.3	$	37
Vested at September 30, 2021											1,802		$	2.77		5.6	$	34

Exercisable at June 30, 2021		1,564		$	3.06		5.3	$	37
Exercisable at September 30, 2021											1,802		$	2.77		5.6	$	34

	Six Months Ended June 30,						Nine Months Ended September 30,
Assumption	2021			2020			2021			2020
Expected price volatility		164.31	%		159.81	%		163.95	%		160.57	%
Sales and marketing		6.19			6.43
Expected term (in years)								6.19			6.45
Risk-free interest rate		1.09	%		0.50	%		0.92	%		0.45	%
Dividend yield		0.00	%		0.00	%		0.00	%		0.00	%
Weighted-average fair value of options granted during the period	$	0.90		$	0.93		$	0.71		$	0.94

	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2021		2020		2021		2020		2021		2020		2021		2020
Research and development	$	3	$	7	$	7	$	14	$	2	$	8	$	8	$	22
Sales and marketing		34		11		65		20
Sales and Marketing										53		29		118		49
General and administrative		259		108		407		149		169		139		576		288
Total stock-based compensation expense	$	296	$	126	$	479	$	183	$	224	$	176	$	702	$	359

	Balance at December 31, 2020		Additions		Deductions			Balance at June 30, 2021		Balance at December 31, 2020		Additions		Deductions			Balance at September 30, 2021
Contract Liabilities: Deferred Revenue	$	2	$	2	$	(2	)	$	2	$	2	$	122	$	(2	)	$	122
Contract Liabilities: Accrued Liabilities (includes contract assets)		573		923		(594	)		902		573		1,213		(1,250	)		536
Total	$	575	$	925	$	(596	)	$	904	$	575	$	1,335	$	(1,252	)	$	658

	Wholesaler/ Pharmacy fees			Cash discounts			Rebates			Returns			Total			Wholesaler/ Pharmacy fees			Cash discounts			Rebate			Returns			Total

Balance at December 31, 2020	$	(91	)	$	(10	)	$	55		$	(527	)	$	(573	)	$	(91	)	$	(10	)	$	55		$	(527	)	$	(573	)
Current provision related to sales made during current period		(137	)		(27	)		(423	)		(336	)		(923	)		(188	)		(38	)		(564	)		(423	)		(1,213	)
Payments		63			19			320			192			594			194			41			499			517			1,250
Balance at June 30, 2021	$	(165	)	$	(18	)	$	(13	)	$	(671	)	$	(902	)
Balance at September 30, 2021																$	(85	)	$	(7	)	$	(10	)	$	(433	)	$	(536	)

	Three Months Ended
	June 30,						Dollar			Percent			Three Months Ended
(in thousands)	2021			2020			Change			Change			September 30,						Dollar			Percent
													2021			2020			Change			Change
Statement of Operations
Sales:
Product revenue, net	$	2,126		$	3,979		$	(1,853	)		(47	%)	$	1,834		$	2,167		$	(333	)		(15	%)
Other revenue, net		7			5			2			40	%		6			3			3			100	%
Total sales, net		2,133			3,984			(1,851	)		(46	%)		1,840			2,170			(330	)		(15	%)

Product cost of goods sold		614			2,040			(1,426	)		(70	%)		493			536			(43	)		(8	%)
Gross profit		1,519			1,944			(425	)		(22	%)		1,347			1,634			(287	)		(18	%)

Research and development		21			115			(94	)		(82	%)		10			125			(115	)		(92	%)
Sales and marketing		1,788			1,423			365			26	%		1,855			1,692			163			10	%
General and administrative		1,569			1,477			92			6	%		1,771			1,879			(109	)		(6	%)
Total operating expenses		3,378			3,015			363			12	%		3,636			3,696			(60	)		(2	%)
Operating loss		(1,859	)		(1,071	)		(788	)		74	%		(2,289	)		(2,062	)		(226	)		11	%

Non-cash loss on changes in fair value of warrant liability		-			(3,772	)		3,772			(100	%)		-			(1,589	)		1,589			(100	%)
Non-cash gain on changes in fair value of embedded derivative liability														-			1			(1	)		(100	%)
Other income, net		-			362			(362	)		(100	%)		-			429			(429	)		(100	%)

Loss before provision for income taxes		(1,859	)		(4,481	)		2,622			(59	%)		(2,289	)		(3,221	)		933			(29	%)
Provision for income taxes		-			(1	)		1			(100	%)		-			-			-			-
Net loss and comprehensive loss	$	(1,859	)	$	(4,482	)	$	2,623			(59	%)	$	(2,289	)	$	(3,221	)	$	933			(29	%)

	Six Months Ended
	June 30,						Dollar			Percent			Nine Months Ended
(in thousands)	2021			2020			Change			Change			September 30,						Dollar			Percent
													2021			2020			Change			Change
Statement of Operations
Sales:
Product revenue, net	$	3,927		$	5,871		$	(1,944	)		(33	%)	$	5,761		$	8,038		$	(2,277	)		(28	%)
Other revenue, net		13			5			8			160	%		19			8			11			138	%
Total sales, net		3,940			5,876			(1,936	)		(33	%)		5,780			8,046			(2,266	)		(28	%)

Product cost of goods sold		1,069			2,621			(1,552	)		(59	%)		1,562			3,157			(1,595	)		(51	%)
Gross profit		2,871			3,255			(384	)		(12	%)		4,218			4,889			(671	)		(14	%)

Research and development		26			124			(98	)		(79	%)		36			249			(213	)		(86	%)
Sales and marketing		3,468			2,983			485			16	%		5,323			4,675			648			14	%
General and administrative		2,756			2,754			2			0	%		4,527			4,633			(106	)		(2	%)
Total operating expenses		6,250			5,861			389			7	%		9,886			9,557			329			3	%
Operating loss		(3,379	)		(2,606	)		(773	)		30	%		(5,668	)		(4,668	)		(1,000	)		21	%

Non-cash loss on changes in fair value of warrant liability		-			(3,635	)		3,635			(100	%)		-			(5,224	)		5,224			(100	%)
Non-cash gain on changes in fair value of embedded derivative liability		-			2			(2	)		(100	%)		-			3			(3	)		(100	%)
Other income, net		2			176			(174	)		(99	%)		2			605			(602	)		(100	%)

Loss before provision for income taxes		(3,377	)		(6,063	)		2,686			(44	%)		(5,666	)		(9,284	)		3,619			(39	%)
Provision for income taxes		-			(1	)		1			(100	%)		-			(1	)		1			(100	%)
Net loss and comprehensive loss	$	(3,377	)	$	(6,064	)	$	2,687			(44	%)	$	(5,666	)	$	(9,285	)	$	3,620			(39	%)

Contractual Obligations	Less than 1 year		1-3 years		3-5 years		More than 5 years		Total		Less than 1 year		1-3 years		3-5 years		More than 5 years		Total
Facility leases	$	295	$	—	$	—	$	—	$	295	$	185	$	—	$	—	$	—	$	185
Equipment leases		16		6		—		—		22		16		1		—		—		17
Total	$	311	$	6	$	—	$	—	$	317	$	201	$	1	$	—	$	—	$	202

		Incorporation by Reference				Filed Herewith
Exhibit Number	Exhibit Description	Form	File Number	Exhibit/ Form 8-K Item Reference	Filing Date
3.1	Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc.	10-K	001-33678	3.1	3/21/2018
3.2	Amendment to the Amended and Restated Certificate of Incorporation, dated June 4, 2018	8-K	001-33678	3.1	6/04/2018
3.3	Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated May 27, 2020	8-K	001-33678	3.1	5/28/2020
3.4	Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated May 24, 2021	8-K	001-33678	3.1	5/24/2021
3.5	Bylaws	8-K	001-33678	3.2	6/29/2010
4.1	Form of Warrant pursuant to the Services Agreement with TLF Bio Innovation Lab, LLC, dated May 13, 2020	8-K	001-33678	4.1	5/18/2020
4.2	Form of July 2020 Warrant	8-K	001-33678	4.1	7/21/2020
10.1	At the Market Offering Agreement, dated May 14, 2021, between NovaBay Pharmaceuticals, Inc. and Ladenburg Thalmann & Co. Inc.	8-K	001-33678	1.1	5/14/2021
31.1	Certification of the Principal Executive Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a)					X
31.2	Certification of the Principal Financial Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a)					X
32.1	Certification by the Chief Executive Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350)					X
32.2	Certification by the Chief Financial Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350)					X
101.INS	Inline XBRL Instance Document					X
101.SCH	Inline XBRL Taxonomy Extension Schema Document					X
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document					X
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase					X
101.LAB	Inline XBRL Taxonomy Extension Labels Linkbase Document					X
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document					X
104	Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101)

Date: ~~August~~November 12, 2021	NOVABAY PHARMACEUTICALS, INC.

	/s/ Justin Hall
	Justin Hall
	Chief Executive Officer (principal executive officer)

Date: ~~August~~November 12, 2021	/s/ Andrew Jones
	Andrew Jones
	Chief Financial Officer (principal financial officer)